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ABSTRACT 
 
Equilibrative nucleoside transporter 1 (ENT1) regulates the bi-directional transfer of 
hydrophilic nucleosides, such as adenosine, across the plasma membrane. Mice lacking 
ENT1 developed calcified lesions resembling diffuse idiopathic skeletal hyperostosis 
(DISH) in humans. By 12 months of age, ENT1
-/-
 mice exhibit spine stiffness, hind limb 
dysfunction, and paralysis. Histological examination of ENT1
-/-
 mice revealed irregular 
accumulations of eosinophilic material in paraspinal ligaments and entheses, 
intervertebral discs, and sternocostal articulations. There was no evidence of 
mineralization in appendicular joints or blood vessels.  Analysis of intervertebral disc 
tissues of 6 month old ENT1
-/-
 and wild-type mice revealed reduced expression of 
mineralization inhibitors, including matrix gla protein (Mgp), ectonucleotide 
pyrophosphatase/phosphodiesterase 1 (Enpp1), progressive ankylosis (Ank), and 
osteopontin (Spp1). The expression of these genes was not altered in tissues which do not 
exhibit ectopic mineralization. Thus, a reduction of proteins that normally prevent soft 
tissue mineralization may induce the ectopic calcification of spinal tissues observed in 
ENT1
-/-
 mice.   
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Chapter 1 
 
 
 
Introduction 
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1.1 Nucleobases, Nucleosides, and Nucleotides  
Nucleobases, also known as nitrogenous bases, are nitrogen-containing 
heterocyclic compounds present in DNA, RNA, nucleotides and nucleosides. Based on 
their structure, nucleobases can be classified into one of two groups. Purine bases contain 
two carbon-nitrogen rings, whereas pyrimidine bases contain one carbon-nitrogen ring 
(1). There are five nucleobases: adenine, guanine, cytosine, thymine (DNA only) and 
uracil (RNA only); adenine and guanine are purine bases and cytosine, thymine and 
uracil are pyrimidine bases.    
Nucleosides (adenosine, guanosine, cytidine, thymidine, uridine and inosine) are 
pyrimidine or purine nitrogenous bases attached to a ribose or 2-deoxyribose ring of a 
pentose sugar via a β-glycosidic bond (2) (Fig. 1.1). Nucleotides are nucleosides bound to 
one or more phosphate groups that covalently attach to the ribose or 2-deoxyribose ring 
of the pentose sugar (3). 
Nucleosides are important biological molecules. These molecules form the 
structural subunit of nucleic acids (DNA and RNA) and nucleotides (such as adenosine 
triphosphate, ATP) that are important in biological processes like cellular replication and 
energy supply (4). Nucleosides and nucleotides have been shown to serve as 
neurotransmitters and neuromodulators (5,6), and play important roles in cell signaling 
through cyclic adenosine monophosphate (cAMP) and adenosine (discussed in section 
1.2). 
 Cytotoxic nucleoside analogues and nucleobases are also used as antiviral, 
antiparasitic and anticancer agents, and induce toxicity by interacting with a large number 
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Figure 1.1: Chemical structures of physiological nucleosides. (modified from Young 
et al., 2008) 
Adenosine, inosine, and guanosine are purine nucleosides while cytidine, uridine, and 
thymidine are pyrimidine nucleosides. 
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of intracellular targets (7-9). Cytotoxic nucleoside analogues compete with physiological 
nucleosides as these molecules share common characteristics, including transport 
mediated by membrane transporters, activation by intracellular processes that retain the 
residues in the cell, and formation of the active derivatives (7) . These agents can exert 
cytotoxic activity by direct incorporation into nucleic acids; by interfering with various 
enzymes involved in the synthesis of nucleic acids; or by modifying the metabolism of 
physiological nucleosides (7,8). 
 
1.2 Adenosine  
Adenosine is a purine nucleoside which plays a critical role in many different 
processes. Adenosine has a well-established role as the building block for the important 
energy molecule ATP, and is also required for nucleic acid synthesis. Free adenosine is 
an important signaling molecule (10). It is recognized as a local regulator of tissue 
function, especially when the available energy supply is unable to meet cellular energy 
demands (11). In cases like this, adenosine is produced by the tissue under stress which 
increases the energy supply (by vasodilation) and decreases the energy demand by acting 
as a negative feedback regulator. 
There has been an increasing interest in the role of purinergic signaling, 
specifically that of adenosine, in the physiology and pathophysiology of musculoskeletal 
tissues (12). Recent studies point to a critical role for purine metabolism in the regulation 
of biomineralization in diseases associated with either insufficient or ectopic 
mineralization (Fig. 1.2) (12-15). A study showed that mutations in the gene encoding  
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Figure 1.2: Schematic of pathways influencing biomineralization.  
Adenosine can regulate cell behaviour and gene expression through cell surface 
receptors. ATP is released into the extracellular fluid and subsequently metabolized by 
cell-surface enzymes. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) 
metabolizes ATP, and releases inorganic pyrophosphate (PPi), which inhibits 
mineralization. Extracellular PPi levels are also regulated by progressive ankylosis 
protein (ANK), a putative transporter that mediates PPi efflux. PPi is metabolized by 
another cell surface enzyme, alkaline phosphatase (ALPL), which produces inorganic 
phosphate (Pi), promoting mineralization. Pi and Ca
2+
 accumulate in matrix vesicles or on 
extracellular matrix components resulting in the crystallization of calcium phosphate, 
leading to formation of hydroxyapatite and thus, matrix calcification. In addition to the 
regulation of biomineralization through changes in PPi levels or PPi:Pi ratio, cells express 
and secrete proteins that can promote or inhibit calcification of the extracellular matrix. 
These proteins include the mineralization inhibitors matrix Gla protein (MGP) and 
osteopontin (SPP1).  
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ENPP1 have been associated with a hypermineralization disorder known as idiopathic 
infantile arterial calcification (13). ENPP1 is an ecto-enzyme responsible for the 
hydrolysis of ATP to adenosine monophosphate (AMP), generating inorganic 
pyrophosphate (PPi), which inhibits soft tissue calcification. Through characterization of 
mice lacking ecto-5’-nucleotidase (Nt5e), Takedachi and colleagues demonstrated that 
adenosine promotes osteoblast differentiation (12). The Nt5e gene encodes the CD73 
cell-surface enzyme, which converts AMP to adenosine. Furthermore, it was found that 
CD73
-/-
 mice had significantly lower bone mineral content, and as a result reduced bone 
volume and thickness, compared to wild-type controls (12). As demonstrated by St. 
Hilarie et al., mutations in NT5E show a genetic association with symptomatic arterial 
and joint calcifications in humans (14). All reported mutations in NT5E resulted in a non-
functional CD73 enzyme. In addition, cultured fibroblasts from affected individuals 
showed reduced expression of the NT5E mRNA and the CD73 protein, increased tissue-
nonspecific alkaline phosphatase (ALPL) enzyme activity, and consequently the 
accumulation of calcium phosphate crystals (14).  ALPL is a cell-surface enzyme 
responsible for hydrolyzing PPi to inorganic phosphate (Pi, which promotes calcification). 
These studies suggest a possible link between adenosine metabolism and the regulation of 
biomineralization. 
1.2.1 Adenosine Bioactivity  
Adenosine, released locally, mediates its physiological and pharmacological 
actions via interactions with G protein-coupled receptors. Extracellular adenosine acts as 
a ligand for purinergic cell surface adenosine receptors; there are four subtypes of these 
receptors – A1, A2a, A2b, A3 – with specific tissue distribution, pharmacology, and 
7 
 
signaling mechanisms (16,17). The A1 and A3 receptors signal through an inhibitory G 
protein (Gi), which inhibits cAMP production by adenylate cyclase. In contrast, the A2a 
and A2b receptors signal through a stimulatory G protein (Gs), which increases cAMP 
production (16,18). cAMP has been shown to induce abnormal calcification of vascular 
smooth muscle cells via a mechanism involving reduction in extracellular PPi 
accumulation (19).  
Bone is a dynamic organ that undergoes continuous remodeling through a balance 
of bone formation and bone resorption. Osteoblasts, which are bone forming cells, 
synthesize new bone, while osteoclasts resorb bone (20,21). Recent studies have shown 
that adenosine receptors are involved in osteoblast and osteoclast differentiation and 
function. Studies demonstrated the presence of all four adenosine receptors in murine 
bone marrow cell osteoclast precursors, and showed that receptors were up-regulated 
during osteoclast differentiation (22). In the A1 receptor-knockout mouse, there was a 
significant increase in bone density and volume due to compromised osteoclast-mediated 
resorption ability (23). Furthermore, the presence of A1 receptor antagonists have been 
shown to inhibit osteoclast formation (24). In contrast to the A1 receptor, activation of the 
A2a receptor inhibits osteoclastogenesis; mice deficient in the A2a receptor show a 
reduction in bone density (25). It has also been reported that the A2a receptor plays a role 
in promoting the proliferation of mouse bone marrow-derived mesenchymal stem cells 
and is up-regulated at later osteoblast differentiation stages (26,27), however the A2b 
receptor is reported as the functionally dominant receptor involved in osteoblast 
differentiation (28). Little is known about the role of the A3 receptor in musculoskeletal 
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tissues, however the receptor is expressed on the surfaces of osteoblasts (29), and its 
selective agonist increases primary osteoblast proliferation (30).  
1.3 Nucleoside Transporters 
As hydrophilic molecules, nucleosides and their analogues require specialized 
glycoprotein transporters to cross the hydrophobic cellular membrane (4,8). Given the 
importance of these molecules in intracellular nucleotide generation, as well as 
extracellular signaling, the ability of cells to accumulate these molecules depends on their 
efficient movement across membranes. In addition, cells incapable of de novo nucleoside 
synthesis, such as enterocytes, bone marrow cells, and certain brain cells require 
transporters to salvage nucleosides from the extracellular environment (4). In mammals, 
nucleoside transport is carried out by seven transporters which are classified into two 
distinct families based on their transport mechanism: the concentrative nucleoside 
transporters (CNTs 1-3, also known as SLC28) and the equilibrative nucleoside 
transporters (ENTs 1-4, also known as SLC29) (4,8,31).    
1.3.1 Concentrative Nucleoside Transporters (CNTs) 
 CNTs are Na
+
-dependent symporters that move nucleosides and nucleobases 
against a concentration gradient. The CNT family consists of three subtypes (CNT1, 
CNT2, and CNT3), all of which differ in their substrate specificities (32). CNT1 prefers 
pyrimidine nucleosides and adenosine, CNT2 prefers purine nucleosides and uridine, and 
CNT3 transports both pyrimidine and purine nucleosides. CNTs are primarily found in 
barrier cell types such as renal and intestinal epithelia, the blood-brain barrier and blood-
testes barrier, and thus play a role in absorption, distribution and elimination of 
nucleosides and their analogues (33).   
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1.3.2 Equilibrative Nucleoside Transporters (ENTs)   
ENTs are Na
+
-independent, facilitative diffusion transporters which transport 
nucleosides bi-directionally down a concentration gradient. ENTs are widely distributed 
among cell types (4,33). The ENT family consists of four members (ENT1, ENT2, 
ENT3,and ENT4) which share an ability to transport adenosine but differ in their abilities 
to transport other nucleosides and molecules (31). For example, ENT2 has a higher 
affinity for inosine than ENT1, and is the only transporter that transports nucleobases. In 
addition, many studies reveal that ENT3 has a similar substrate specificity as ENT2, but a 
lower affinity (31). The distribution of these transporters is not homogenous among 
tissues, and expression is regulated in a cell-type specific manner. ENT orthologues have 
been identified in many different eukaryotic species; over the course of evolutionary 
time, the protein has been found to be highly conserved, highlighting the physiological 
significance of ENTs (34). It should be noted that mice have the same nucleoside 
transporter proteins as humans and share similar characteristics (Table 1.1); although 
studies to date have suggested that certain ENTs are ubiquitous, expression has yet to be 
investigated in all tissues (35).  
ENT1 and ENT2 have been the most extensively characterized transporters and 
were distinguished based on their sensitivity to inhibition by nitrobenzylthioinosine 
(nitrobenzylmercaptopurine riboside; NBMPR). ENT1 is sensitive to inhibition by 
NBMPR at ηmolar concentrations and is referred to as the es transporter, or equilibrative-
sensitive. ENT2 is resistant to inhibition by NBMPR, requiring µmolar concentrations 
and is referred to as the ei transporter, or equilibrative-insensitive (Fig. 1.3) (8).  
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Table 1.1: Properties of the mammalian nucleoside transporters (modified from 
Young et al., 2008) 
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Figure 1.3: Mammalian nucleoside transport systems of the equilibrative nucleoside 
transporter (ENT) and concentrative nucleoside transporter (CNT) protein families. 
(modified from Young et al., 2008) 
ENTs are Na
+
-independent, facilitative diffusion transporters which transport nucleosides 
and nucleobases bi-directionally down a concentration gradient. ENT1 and ENT2 are 
distinguished based on their sensitivity to inhibition by nitrobenzylthioinosine (NBMPR). 
ENT1 is sensitive to inhibition by NBMPR at nanomolar concentrations. ENT2 is 
resistant to inhibition by NBMPR. CNTs are Na
+
-dependent symporters that move 
nucleosides and nucleobases against a concentration gradient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ENT2 ENT1 
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ENT1 is ubiquitously distributed in human and rodent tissues, but abundance 
varies from tissue to tissue. For example, human ENT1 (hENT1) is most abundant in the 
frontal and parietal lobes of the cortex, thalamus and basal ganglia (36). hENT1 
expression has also been noted in the brain, heart, liver, placenta, adrenal gland, 
erythrocytes, stomach and vascular endothelium (37). With respect to mouse ENT1 (he), 
expression has been found in similar tissues such as the heart, brain, and liver, as well as 
the colon, spleen, and kidney (35). Although ENT1 is primarily found on the surface of 
cells, functional hENT1 has also been associated with the membranes of the endoplasmic 
reticulum and nuclear envelope, suggesting that this transporter may play a role in the 
passage of nucleosides between these compartments and the cytosol (38). A stark 
difference that should be noted is that hENT1 has also been found functionally expressed 
in the mitochondria, whereas mENT1 has no association with the mitochondria (39,40). 
   ENT2 differs from ENT1 in its ability to transport nucleobases such as 
hypoxanthine, in addition to nucleosides (31,41). mENT2 mRNA has been identified in a 
variety of tissues such as the small intestine, kidney, spleen, heart, and liver, but is 
particularly abundant in skeletal muscle (35). 
ENT3 and ENT4 are less characterized but appear to have a more specialized role 
in the cell (8,42). The ENT3 transcript and protein is abundant in many human and rodent 
tissues but is highly expressed in placental tissue (42). Unlike ENT1 and ENT2, ENT3 is 
not found at the plasma membrane, but rather is located on intracellular membranes (42). 
ENT3 contains an endosomal/lysosomal characteristic motif, which along with its ability 
to optimally function at a pH of 5.5, suggests that the location of the transporter is in an 
acidic, intracellular compartment such as the lysosome (8,42,43). ENT4, present at the 
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cell surface, was originally identified as a monoamine/organic transporter and was named 
plasma membrane monoamine transporter (PMAT), since it transports organic cations 
such as MPP+, dopamine and serotonin (44-46). It was later discovered that ENT4 was 
able to efficiently transport adenosine at an acidic pH of 5.5 (47), and hypothesized to 
contribute in the regulation of extracellular adenosine concentrations under acidic 
conditions associated with ischemia (8).  ENT4 is expressed primarily in the heart, liver 
and brain (8).  
It is important to note that the reason and degree of functional redundancy 
between ENTs is not known; it is unclear why so many cells and tissues express multiple 
nucleoside transporters with similar or overlapping substrate selectivity (35).  
 
1.4 ENT1-null mice (ENT1
-/-
) 
The ENT1
-/- 
mouse was created by Dr. Doo-Sup Choi at the Mayo Clinic College 
of Medicine. The ENT1
-/- 
mouse was generated on a C57BL/6J x 129X1/SyJ background 
using the targeting vector pKSloxPNT-mod to delete coding exons 2 to 4 (Fig. 1.4). This 
targeting strategy eliminated 425 of the 1380 base pairs in the protein coding-region (48) 
and produced a non-functional protein.  
Initial studies demonstrated that at 3 months of age, ENT1
-/- 
mice had <10% lower 
body weight, but showed no differences in open-field locomotor activity, and had no 
evidence of gross anatomical abnormalities in the brain compared to their wild-type (WT) 
littermate controls (48). There were also no significant differences reported in 
spontaneous mortality rates up to 6 months of age.    
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Figure 1.4: Generation of ENT1-null mice. (modified from Choi et al., 2004) 
Figure shows the organization of the gene encoding mouse ENT1, the targeting construct, 
and the allele resulting from homologous recombination. Boxes represent the targeted 
exons (2–4), which span 425 base pairs. Gray arrowheads represent loxP sequences, the 
recognition sites for Cre recombination, and deleted coding exons 2-4.  
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These
 
mice were developed to investigate the role of adenosine transport in the 
central nervous system pathways regulating alcohol consumption (48,49). In these 
studies, ENT1
-/- 
mice consumed significantly higher amounts of ethanol, and had a greater 
preference for ethanol than water. Despite the increase in ethanol consumption, these 
mice demonstrated a decreased ataxic effect of ethanol. This behavior was associated 
with a reduced stimulation of A1 receptors due to a decrease in endogenous adenosine 
tone and not due to the loss of A1 receptors or a decrease in A1 receptor affinity (48). 
ENT1
-/- 
mice have also been shown to exhibit reduced anxiety-like behaviors, specifically 
mediated by A1 receptors (49). 
Previous studies in the Hammond lab established that microvascular endothelial 
cells (MVECs) isolated from ENT1
-/- 
mice demonstrate compromised nucleoside 
transport compared to cells isolated from WT controls. There was no compensation 
reported for the loss of ENT1 by other transporters (50). In contrast, MVECs isolated 
from ENT1
-/- 
mice show an increase in the A2a receptor and adenosine deaminase (Ada) 
mRNA transcript and protein compared to WT cells (50). Ada is a metabolic enzyme that 
converts adenosine to a related nucleoside, known as inosine. At 2-3 months of age, 
ENT1
-/- 
mice were also found to have a significantly lower blood pressure, possibly due 
to the 2.8-fold increase reported in circulating adenosine concentrations. Furthermore, 
others have demonstrated that cardiomyocytes from ENT1
-/- 
mice appear to be protected 
from ischemic insult and that ENT1
-/-
 mice show decreased myocardial infarction in 
response to ischemia and hypoxia (10). 
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1.5 Connective Tissues 
 During previous studies in the Hammond lab using the ENT1
-/- 
mice, it was 
observed that these mice develop a mineralized soft connective tissue phenotype. 
Connective tissue is the most diverse tissue type with a wide variety of functions; it can 
be considered the “glue” that holds the body together. All forms of connective tissue are 
made up of: (i) extracellular matrix molecules, (ii) amorphous matrix called ground 
substance, and (iii) stationary and migrating cells (51). Depending on the structural 
requirements, the proportions of these three components vary from one part of the body 
to another. The extracellular matrix (ECM) consists of collagenous, elastic, and reticular 
fibers. The amorphous matrix surrounds the cellular and fibrous components and is made 
up of glycosaminoglycans (GAGs), proteoglycans (PGs) and glycoproteins. Fibroblasts 
are the principle cells of connective tissue that synthesize all of the ECM components 
(collagen, elastic and reticular fibers, and the complex carbohydrates of the ground 
substance) (52). Specialized connective tissue includes cartilage, blood, bone, ligaments, 
and intervertebral discs.  
1.5.1 Cartilage 
 Cartilage is an avascular and aneural tissue composed of two distinct components, 
chondrocytes and the ECM (53). Chondrocytes are specialized cells of mesenchymal 
origin that produce and, to some degree, maintain the cartilage tissue. More than 95% of 
the cartilage volume consists of the ECM, which is the functional element of this tissue 
(53,54). Despite the low fraction of chondrocytes in the cartilage, these cells are 
important as they produce the matrix that provides mechanical stability to the tissue 
(52,54). The composition of the ECM is important to the survival of chondrocytes; the 
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large ratio of GAGs to type II collagen fibers in the matrix allow for the diffusion of 
nutrients from blood vessels in surrounding tissue to the chondrocytes (52).  
Cartilage is a key tissue in the development of the fetal skeleton and growing 
bones (52). In healthy cartilage, physiological remodeling of the cartilage is 
accomplished through a balance between matrix synthesis and matrix degradation (55). 
Based on the characteristics of their matrix, there are three types of cartilage that differ in 
appearance and properties: hyaline cartilage, elastic cartilage and fibrocartilage.  
1.5.2 Hyaline cartilage, elastic cartilage and fibrocartilage  
 Hyaline cartilage consists predominantly of type II collagen fibers, GAGs, PGs, 
and glycoproteins and is found on the articular surfaces of synovial joints, costal 
cartilages of the rib cage, the nasal cavity and the trachea. In early fetal development, 
hyaline cartilage forms the template for the skeleton, acting as the precursor of bones that 
develop by endochondral ossification (56).  
 Elastic cartilage is characterized by the presence of elastic fibers within an ECM 
with a composition otherwise similar to hyaline cartilage; the elastin fibers and collagen 
are arranged in a wavy pattern that makes it flexible. It is found in the outer ear and the 
epiglottis of the larynx. In contrast to hyaline cartilage, elastic cartilage does not calcify 
with age (52).  
 Fibrocartilage is rich in type I collagen fibers in addition to the ECM 
composition of hyaline cartilage; it is a combination of dense regular connective tissue 
and hyaline cartilage (52). It is the only type of cartilage that contains type I collagen in 
addition to the normal type II. Fibrocartilage is a tough form of cartilage that consists of 
rows of chondrocytes in lacunae between parallel bundles of collagenous fibers, which 
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allow the tissue to be strong and flexible. Fibrocartilage lacks a perichondrium, which is a 
layer of dense irregular connective tissue that surrounds the cartilage of developing bone, 
and can be found around hyaline and elastic cartilage. Fibrocartilage is present in the 
annulus fibrosus of intervertebral discs (IVDs), menisci of the knee joint, articular discs 
of the sternoclavicular and temporomandibular joints, the pubic symphysis and certain 
insertion points of tendons (52). Fibrocartilage is a transitional tissue where soft 
connective tissues anchor into bone or cartilage, especially at joints. Fibrocartilage at 
these locations serves as a shock absorber, and provides resistance to both compressive 
and shearing forces (52). The tissue provides support and rigidity to attached and 
surrounding structures, and is the strongest of the three types of cartilage.  
 
1.6 Fibrocartilaginous Tissues of the Axial Skeleton 
1.6.1 The Intervertebral Disc 
The vertebral column makes up a part of the axial skeleton, and supports the head 
and encloses the spinal cord. It consists of alternating vertebral body (VB) bones and soft 
connective tissue IVDs. The mouse vertebral column can be divided into five distinct 
regions: cervical (7 vertebrae), thoracic (13 vertebrae), lumbar (6 vertebrae), sacral (4 
fused vertebrae), and caudal (28 vertebrae) (57,58).  
The IVD is a specialized connective tissue that: protects against mechanical 
loading delivered by the body mass; acts as the spine’s shock absorbing system; and 
provides limited vertebral motion, such as extension and flexion (59,60). The IVD is 
composed of three distinct yet interdependent tissues: 1) nucleus pulposus (NP);             
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2) annulus fibrosus (AF) (inner annulus fibrosus, IAF; outer annulus fibrosus, OAF); and 
3) cartilage endplates (CEP) (Fig. 1.5). 
The NP is a highly-hydrated gelatinous tissue in the center of the IVD, formed 
from the embryonic notochord (61). The NP is rich in proteoglycans and water and is 
held together by a network of type II collagen and elastin fibers. It contains two distinct 
cell types, the larger notochordal cells and their smaller mature derivatives known as 
chondrocyte-like nucleus pulposus cells (61,62). The major proteoglycan of the NP is 
aggrecan, which is a high molecular weight proteoglycan, that consists of 100-150 
sulfated GAG chains (such as chondroitin sulfate and keratin sulfate) attached to a 
protein core (63). The negatively charged GAG chains of aggrecan draw in water (64), 
and allows the NP to distribute hydraulic pressure in all directions, enabling the IVD to 
resist compression and maintain its height and turgor (65-67). The amount of water in the 
NP varies throughout the day, depending on the activity (60).  
The fibrocartilaginous AF makes up the peripheral portion of the disc, which 
serves to contain and protect the NP. The cells of the OAF have been described as 
fibroblast-like, while the cells in the IAF are more rounded. The IAF is rich in 
proteoglycans and type II collagen, where GAGs are intertwined between bundles of 
collagen (68,69). The IAF has the appearance of lamellae and is a specialized structure as 
it serves as the transition zone between the gelatinous NP and the ligamentous-like outer 
part of the annulus fibrosus, the OAF (61,70). The composition and organization of the 
OAF is more ligamentous and is formed by concentric lamellae, consisting mainly of 
type I collagen. The type 1 collagen fibers of the AF run in oblique sheets, and serve to 
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Figure 1.5: Schematic overview of an intervertebral disc (IVD). (Modified from Kurtz 
S, Edidin A. Spine Technology Handbook. 1 edn. Elsevier Academic Press, 2006) 
Figure shows the gelatinous nucleus pulposus in the centre, surrounded by the fibrous 
annulus fibrosus, and the cartilaginous endplates adjacent to the vertebral body. The 
lamellar structure of the annulus fibrosus is also evident. Orientation of the IVD is 
denoted as axial, radial and circumferential.   
 
 
 
 
 
 
 
 
 
Axial 
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anchor into the adjacent vertebral endplate (70,71). The direction of these fibers in 
successive layers alternate, with one layer crossing the other at angles of 30-60 degrees; 
this property provides tensile strength to the annulus fibrosus, allowing it to be stretched 
or extended.   
The endplates are distinct regions found above and below the IVD between 
adjacent vertebrae. The CEP consists of a thin layer of hyaline cartilage between the disc 
and vertebral bodies, and similarly, is rich in type II collagen and proteoglycans (72,73). 
Through diffusion, the CEP supplies nutrients from blood vessels in the vertebral body to 
the inner two-thirds of the AF and the entire NP (74). 
1.6.2 Paraspinal Ligaments 
Ligaments are a type of dense connective tissue, where fiber bundles run in a 
parallel arrangement to provide tensile strength. Paraspinal ligaments are fibrous bands of 
dense connective tissue; and serve to provide structural flexibility, strength and stability 
to the vertebral column (Fig. 1.6). There are two main ligaments termed the anterior 
longitudinal ligament (ALL) and the posterior longitudinal ligament (PLL). The ALL is 
a thick, broad fibrous band that lies on the anterior surface of the VBs and IVDs and 
prevents hyperextension of the spine. The PLL runs on the posterior surface of the VBs 
and IVDs inside the spinal canal and prevents hyperflexion of the spine; the ligament is 
narrower and weaker than the ALL (75). The ALL and PPL merge with the AF of the 
IVD and are well innervated (76). There are also additional ligaments associated with the 
spine that provide further support and strength. The ligamentum flavum is a thick 
ligament which connects laminae of adjacent vertebrae and is part of the posterior wall of 
the vertebral column. There are also two ligaments that connect neighboring spinous 
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Figure 1.6: Schematic overview of paraspinal ligaments associated with the 
vertebral column. (Reproduced from: Save Your Aching Back and Neck, A Patient's 
Guide by Eidelson, 2002)  
Figure shows the organization of the paraspinal ligaments that provide structural 
flexibility, strength and stability to the vertebral column. The paraspinal ligaments consist 
of the anterior longitudinal ligament, posterior longitudinal ligament, ligamentum flavum, 
interspinous ligament, supraspinous ligament, intertransverse ligament, and the facet 
capsulary ligament.  
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processes, portions of the vertebrae that extend towards the back. The interspinous 
ligament runs between the top and bottom of the processes, whereas the supraspinous 
ligament is a stronger ligament found along the posterior surface (75). These ligaments 
insert into the bone, through fibrocartilaginous intermediate regions.  
1.6.3 Sternum 
 The sternum is an elongated, flattened bone which forms the middle anterior 
portion of the thorax, and its margins connect with the cartilages of the first seven pairs 
of ribs (75). In humans, the sternum consists of three parts: the manubrium, the body, and 
the xiphoid process (77). It is important to note that before puberty, the body of the 
sternum consists of four sternebrae which eventually fuse to form one structure; however 
this is not the case in mice (77,78). The sternum in mice is made up of six components: 
the manubrium (rostral), followed by three separate sternebrae, the xiphisternum, and the 
xiphoid cartilage (58). In humans, the sternomanubrial joint (between the sternum and 
manubrium)  is considered a cartilaginous joint, where the articulating ends are covered 
by hyaline cartilage and linked by fibrocartilage and ligaments (79). 
 
1.7 Extracellular Matrix Calcification 
Biological mineralization is a cell-regulated event that, under normal 
physiological conditions, is restricted to the extracellular matrices of bone, dentin, 
cementum, enamel and cartilage. Mineral deposition is an extremely balanced and tightly 
controlled process (80). There appears to be two fundamental models for how mineral 
deposition in bone is initiated: the cell-mediated model and the matrix-regulated model. 
In the cell-mediated model, authors suggest that osteoblasts, which are bone forming 
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cells, secrete matrix vesicles (MVs) which control the initial site of mineral deposition 
(52). In a mineralization-inducing environment, MVs are proposed to bud off of the outer 
cell plasma membrane in a polarized manner towards newly formed osteoid (81). Several 
studies suggest that as MVs initially bud off, the vesicles do not contain crystals, but 
rather that the first crystalline mineral appears after the MV has been immobilized in the 
collagen matrix (81). These vesicles contain enzymes, and accumulate calcium (Ca
2+
) 
and inorganic phosphate (Pi or PO4
3-
). These components allow for the crystallization of 
calcium phosphate, leading to the formation of initial hydroxyapatite 
(HA,  Ca10(PO4)6(OH)2) crystals within the lumen of MVs (82). Once the mineral has 
reached a certain size, the MV ruptures, and initial crystals of HA grow rapidly to join 
crystals produced around other matrix vesicles, contributing to extracellular matrix 
calcification (81,83). It should be noted that the mechanism by which MVs accumulate 
Ca
2+
 and Pi, and the mechanism by which crystals penetrate through the membrane are 
not yet fully understood.  
On the other hand, it has been proposed that the extracellular matrix mineralizes 
directly, without the involvement of matrix vesicles (84,85). This matrix-regulated model 
states that all components necessary for the initiation and deposition of calcification are 
an inherent property of the extracellular matrix once they have been secreted. It has been 
suggested that nucleation occurs within gaps of the collagen bundles and crystals 
subsequently grow, mediated by certain non-collagenous proteins, which associate with 
the extracellular matrix (84,85). 
In bone, there are several events that occur to enable mineralization (52). First, 
alkaline phosphatase (ALPL) increases the Pi concentration, and hydrolyzes the 
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mineralization inhibitor, PPi. It is known that PPi antagonizes the formation of HA 
crystals, hence the importance of having a tight balance between the levels of 
extracellular Pi and PPi for normal mineral deposition  (86). Bone sialoprotein (BSP), 
which is a major protein in the mineralized matrix of bone has been proposed to nucleate 
crystals, and initiate the deposition of calcium phosphate (87,88). BSP and several other 
bone proteins play a critical role in the growth of crystals, and extracellular matrix 
calcification.     
Many genes involved in regulating mineral deposition have been identified (Fig. 
1.2). ATP is released by as yet unresolved pathway into the extracellular fluid, and 
metabolized by cell-surface enzymes, such as ectonucleotide pyrophosphatase/ 
phosphodiesterase 1 (ENPP1), which releases PPi (13). Extracellular PPi levels can also 
be regulated by progressive ankylosis (ANK), a transmembrane protein postulated to 
mediate PPi efflux [84]. PPi is metabolized by the cell-surface enzyme ALPL, to Pi, 
which promotes mineralization. The Nt5e gene encodes ecto-5’-nucleotidase (CD73), an 
enzyme that converts AMP to adenosine and Pi. Matrix gla protein (MGP) (89) and 
osteopontin (SPP1) (90) are matrix proteins that inhibit mineralization. 
 
1.8 Disorders of Tissue Mineralization  
 Abnormal calcification of the ECM of soft connective tissues is associated with a 
number of pathologies including vascular disease, chronic kidney disease, and skeletal 
disorders (91-94). Soft tissues do not mineralize under normal conditions but, under 
certain pathological conditions, tissues such as articular cartilage and cardiovascular 
tissues are prone to mineralization (95,96). Mutations in many of the genes (mentioned in 
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section 1.7, and Fig. 1.2) affect the rate of generation, transport and degradation of PPi, 
leading to an unbalanced level, which ultimately leads to ectopic deposition of mineral 
(12-15,86).  For example, a study showed that mutations in the gene encoding ENPP1 
have been associated with a hypermineralization disorder known as idiopathic infantile 
arterial calcification (13). In mice, mutations of Ank lead to arthritis, ectopic crystal 
formation and joint fusion throughout the body (97); in humans, dominant mutations 
were associated with craniometaphyseal dysplasia (98). A study by Yadav et al. reports 
that a disruption in Alpl prevents skeletal mineralization (15). MGP deficiency in mice 
resulted in premature calcification, and aberrant mineralization in normal cartilage 
including the growth plate, which eventually lead to short stature, osteopenia and 
fractures, and severe arterial calcification, which lead to premature death  (99).  
1.8.1 Ossification of the Posterior Longitudinal Ligament and Diffuse Idiopathic 
Skeletal Hyperostosis 
Ossification of paraspinal ligaments is identified in the middle-aged and elderly, 
and can be diagnosed as one of two non-inflammatory conditions: (1) ossification of the 
posterior longitudinal ligament (OPLL), or diffuse idiopathic skeletal hyperostosis 
(DISH, formally known as Forestier disease (100)).  
OPLL is the abnormal calcification of the posterior longitudinal ligament, and has 
the highest incidence in Japan (101). OPLL is commonly detected in the cervical region 
of the spine, where lesions can compress the spinal cord resulting in neurological 
complications. This condition is twice as common in woman and symptoms often  
present between the ages of 50 to 60 (102). Since OPLL is commonly found in Asian 
populations, genetic factors are believed to play a role in its development. Many genes 
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have been associated with OPLL, including polymorphisms in collagen 11A2 
(COL11A2) (103), collagen 6A1 (COL6A1) (104) and mutations in ectonucleotide 
pyrophosphatase/phosphodiesterase 1 (ENPP1) (105).  
The overall prevalence of DISH is estimated to be around 6-12% of North 
Americans (106). As reported by The Arthritis Society, DISH is the second most common 
form of arthritis, after osteoarthritis. DISH involves the pathological calcification of the 
anterolateral spinal ligaments, at ligamentous attachments known as entheses, and para-
articular soft tissues (107-109). DISH is a progressive condition in which calcifications 
accumulate over many years forming flowing calcified material along sides of the spine 
vertebrae (Fig. 1.7). DISH is often underdiagnosed and widely misdiagnosed (110). It is 
predominantly diagnosed though radiographs of the thoracic spine or chest, which reveal 
distinct calcified outgrowths along the vertebrae (111). There are three radiographic 
criteria for DISH: 1) flowing calcifications along anterolateral aspect of at least four 
continuous vertebral bodies; 2) preservation of disc height in involved areas (in contrast 
to degenerative disc disease); and 3) absence of bony ankylosis of facet joints and 
absence of sacroiliac erosion, sclerosis or fusion (in contrast to ankylosing spondylitis) 
(112). DISH often presents as back pain and stiffness, and is associated with increased 
vertebral fractures in the elderly (113) and in severe cases, dysphagia (114) and 
compression of the spinal cord and nerve roots (114-116). To date, no single gene defect 
has been associated with DISH; however single nucleotide polymorphisms in the 
COL6A1 and FGF2 genes have been shown to confer genetic susceptibility to DISH 
(117,118). The etiology of DISH is unknown; however numerous studies have associated 
obesity, hypertension, diabetes mellitus, hyperinsulinemia, dyslipidemia, elevated growth 
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Figure 1.7: Diffuse idiopathic skeletal hyperostosis (DISH) in 55-year-old man. 
(Reproduced from: Journal of Clinical Neuroscience 17: 336-1338, 2010) 
Computed tomography scan in the sagittal orientation of the cervical region shows 
ventral calcifications at the level of C4 to C6 (white arrow). Patient presented with a 
history of progressive dysphagia, associated with neck stiffness.  
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hormone levels, elevated insulin-like growth factor-1, and hyperuricemia with DISH 
(119-121). Pathological findings of DISH have been reported in the anterior longitudinal 
ligament, paraspinal connective tissue, and annulus fibrosus of the intervertebral disc 
(112); lesions are thought to originate in fibrocartilaginous structures including entheses 
(122). 
 
1.9 Rationale, Objectives and Hypotheses  
Preliminary observations suggest that mice lacking the gene encoding ENT1 
developed lesions of ectopic mineralization which resemble DISH in humans. With 
advanced age, ENT1
-/-
 mice displayed a stiff back, hind limb dysfunction and eventual 
hind limb paralysis at 12 months of age. Preliminary micro-computed tomography (µCT) 
scans and histological analyses revealed hypermineralized lesions began in the cervical-
thoracic region of the spine and extended towards the lumbar region with advanced age. 
Since the etiology and mechanism of DISH is unknown, the ENT1
-/- 
mouse may 
provide a model to investigate mechanisms underlying ectopic mineralization and 
evaluate therapeutics for preventing pathological calcification in DISH and related 
disorders. The ultimate goal of this study was to investigate how the loss of the gene 
encoding ENT1 leads to the aberrant skeletal phenotype demonstrated in the ENT1
-/-
 
mice. Specifically, it was hypothesized that: loss of ENT1 leads to progressive 
accumulation of ectopic mineral in paraspinal tissues due to altered expression of 
genes that regulate biomineralization.  
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We sought to explore this hypothesis with the following specific objectives: 
1) Characterize pathological changes in paraspinal tissues in ENT1-/- mice over time 
pertaining specifically to hypermineralization. 
2) Determine changes in the expression of genes associated with adenosine transport 
and metabolism, as well as, extracellular matrix mineralization in the ENT1
-/-
 
mice compared to wild-type controls. 
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2.1 Chapter Summary 
 
Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory 
spondyloarthropathy, characterized by ectopic calcification of spinal tissues. Symptoms 
include spine pain and stiffness, and in severe cases dysphagia and spinal cord 
compression. The etiology of DISH is unknown and there are no specific treatments. 
Recent studies have suggested a role for purine metabolism in the regulation of 
biomineralization. Equilibrative nucleoside transporter 1 (ENT1) transfers hydrophilic 
nucleosides, such as adenosine, across the plasma membrane. In mice lacking ENT1, we 
observed the development of calcified lesions resembling DISH. By 12 months of age, 
ENT1
-/-
 mice exhibited signs of spine stiffness, hind limb dysfunction, and paralysis. 
Micro-CT revealed ectopic mineralization of paraspinal tissues in the cervical-thoracic 
region at 2 months of age, which extended to the lumbar and caudal regions with 
advancing age. Energy-dispersive X-ray microanalysis of lesions revealed a high content 
of calcium and phosphorus with a ratio similar to that of cortical bone. At 12 months of 
age, histological examination of ENT1
-/- 
mice revealed large, irregular accumulations of 
eosinophilic material in paraspinal ligaments and entheses, intervertebral discs and 
sternocostal articulations. There was no evidence of mineralization in appendicular joints 
or blood vessels, indicating specificity for the axial skeleton. Plasma adenosine levels 
were significantly greater in ENT1
-/- 
mice than in wild-type, consistent with loss of ENT1 
– a primary adenosine uptake pathway. There was a significant reduction in the 
expression of Enpp1, Ank, and Alpl in intervertebral discs from ENT1
-/- 
mice compared to 
wild-type mice. Elevated plasma levels of inorganic pyrophosphate in ENT1
-/-
 mice 
indicated generalized disruption of pyrophosphate homeostasis. This is the first report of 
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a role for ENT1 in regulating the calcification of soft tissues. Moreover, ENT1
-/- 
mice 
may be a useful model for investigating pathogenesis and evaluating therapeutics for the 
prevention of mineralization in DISH and related disorders. 
 
2.2 Introduction 
 
Abnormal calcification of the extracellular matrix of soft connective tissues is 
associated with a number of pathologies including vascular disease, chronic kidney 
disease, and multiple skeletal disorders (1-4). Ossification of paraspinal ligaments is 
often detected in middle-aged and elderly patients, presenting as one of two non-
inflammatory spondyloarthropathies: (1) diffuse idiopathic skeletal hyperostosis (DISH, 
formerly referred to as Forestier disease (5)), which involves calcification of spinal 
ligaments and extra-axial structures including entheses (4); and (2) ossification of the 
posterior longitudinal ligament (OPLL), which is common in the Japanese population (6). 
Although often misdiagnosed, DISH and OPLL are distinct from degenerative disc 
disease, osteoarthritis, and ankylosing spondylitis (7).  
DISH is typically diagnosed using radiographs of the thoracic spine or chest, 
which demonstrate: (1) flowing calcifications along the anterolateral aspect of at least 
four contiguous vertebral bodies; (2) preservation of intervertebral disc height (in contrast 
to degenerative disc disease); and (3) absence of bony ankylosis of facet joints and 
absence of sacroiliac erosion, sclerosis or fusion (in contrast to ankylosing spondylitis) 
(8). DISH often manifests as back pain associated with limited range of spinal motion, 
but can progress to the extent that lesions interfere with neighbouring structures, 
including compression of the spinal cord and nerve roots (9,10). Lesions in DISH can 
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also cause dysphagia (11), and DISH is associated with increased susceptibility to spinal 
fractures (12) and postsurgical heterotopic ossifications (13). Correlative studies have 
associated obesity, hypertension, diabetes mellitus, hyperinsulinemia, dyslipidemia, 
elevated growth hormone levels, elevated insulin-like growth factor-1, and hyperuricemia 
with DISH (14-16). It has been proposed that DISH lesions originate in fibrocartilaginous 
structures including entheses (17); however, due to the lack of suitable animal models, 
the underlying pathogenesis remains obscure.  
Several factors including genetic background have been postulated to be involved 
in the etiology of DISH; however to date no single gene defect has been associated with 
the disease. In a subset of DISH patients of Asian descent, single-nucleotide 
polymorphisms in the COL6A1 and FGF2 genes have recently been shown to confer 
genetic susceptibility to DISH (18,19). In contrast to DISH, OPLL has been studied 
extensively in the Japanese population, leading to identification of a number of associated 
genes, including NPSS (20,21), COL11A (22), COL6A1(23), BMP2 (24), TGFβ (25), and 
FGFR1 (19).  
Recent advances point to a critical role for purine metabolism in the regulation of 
biomineralization in diseases associated with either insufficient or ectopic mineralization 
(26-31). For example, mutations in the gene encoding ectonucleotide pyrophosphatase/ 
phosphodiesterase 1 (ENPP1) have been associated with hypermineralization disorders 
(26,27). Moreover, a recent study has linked ectopic arterial and joint calcifications with 
loss of ecto-5'-nucleotidase (NT5E) function leading to decreased levels of extracellular 
adenosine (28). To further explore the role of purine metabolism in the regulation of 
biomineralization, we examined the phenotype of the mouse lacking the gene encoding 
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the nucleoside transporter ENT1. ENT1 (equilibrative nucleoside transporter 1 or solute 
carrier family 29 member 1, encoded by the Slc29a1 locus) is the predominant nucleoside 
transporter expressed in mammalian cells (32). This sodium-independent, facilitative 
diffusion carrier is responsible for the movement of hydrophilic nucleosides, such as 
adenosine, across biological membranes. Loss of ENT1 activity would be expected to 
modify extracellular adenosine levels, thus altering overall purine metabolism and 
signaling through adenosine receptors. The present study reports the novel skeletal 
phenotype of the ENT1
-/- 
mouse that resembles DISH in humans.  
 
2.3 Materials and Methods 
2.3.1 Animals 
 ENT1
-/-
 mice were generated through targeted deletion of exons 2 to 4 of the gene 
encoding ENT1 by a cre-loxP targeting strategy (33). ENT1
-/-
 mice were backcrossed 
with C57BL/6 mice. The mouse colony was maintained through the breeding of 
heterozygous animals (ENT1
+/-
) to obtain wild-type (ENT1
+/+
) and knockout (ENT1
-/-
) 
littermates. Mice were housed in standard cages and maintained on a 12-hour light/dark 
cycle, with rodent chow and water available ad libitum. Genotyping was performed as 
described (34). Given the increased reported prevalence of DISH in males (25% of men 
versus 15% of women over 50 years of age) (35), male mice were used for all 
experiments. Mice were euthanized at the following ages: 1 month (4-4.5 weeks), 2 
months (8-11 weeks), 4 months (16-18 weeks), 6 months (26-30 weeks) and 12+ months 
(12-17 months). Experimental results were derived from groups of at least 3 wild-type 
and 3 ENT1
-/-
 mice. All aspects of this study were conducted in accordance with the 
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policies and guidelines set forth by the Canadian Council on Animal Care and were 
approved by the Animal Use Subcommittee of the University of Western Ontario, 
London, ON, Canada.  
 
2.3.2 Micro-computed tomography imaging 
 Micro-computed tomography (µCT) scanning, reconstruction and analysis were 
performed based on reported protocols (36) with the following modifications. Formalin-
fixed or snap-frozen whole mice were imaged at Robarts Research Institute (London, 
ON, Canada) using a dedicated laboratory µCT scanner (eXplore speCZT; GE Healthcare 
Biosciences). Data were acquired with an X-ray tube voltage of 90 kV and a current of 40 
mA. In one continuous rotation, 900 views were obtained at an angular increment of 0.4
o
 
and an exposure interval of 16 ms per view. The total scan time was 5 minutes per 
animal. A calibrating phantom, consisting of a vial of water, air and a synthetic bone-
mimicking epoxy (SB3; Gammex Inc. Middleton, WI, USA), was imaged together with 
the specimens. Images were acquired at isotropic voxel size of 100 m and reconstructed 
into 3D images, using a modified cone-beam algorithm (37). The reconstructed data were 
expressed in Hounsfield units by calibrating the gray-level values against those of water 
and air. Mineralized tissue density within the volume of interest was expressed as 
hydroxyapatite (HA) equivalent density (mg HA cm
-3
), based on the calibration provided 
by the SB3 bone-mimicking material. 
Images acquired for each animal were scored for severity of ectopic 
mineralization, based on the percentage of affected sites within the spine (sites defined as 
an intervertebral disc and/or associated paraspinal ligaments and entheses) in each 
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anatomical region (cervical, thoracic, lumbar and caudal). Values ranged from 0 to 4, 
with a score of 0 reflecting no detectable mineralized lesions, 1 indicating lesions 
involving 0 to 30% of sites within the anatomical region, 2 indicating lesions involving 
30 to 60% of sites, 3 indicating lesions involving 60 to 90% of sites and 4 indicating 
lesions involving 90 to 100% of sites.  
 
2.3.3 Measurement of mineralized tissue density 
 Using data acquired by µCT, quantification of the density and volume of 
mineralized tissues was performed in a region of interest restricted to the spine (C1 to 
sacrum), rib cage, and sternum. For this purpose, a 3D volume of interest was defined by 
an operator within each volume image, using manually drawn contours lofted to create a 
volume that included only the anatomy of interest (MicroView 2.2, GE Healthcare 
Biosciences). Three measurements were obtained within this volume of interest: the 
volume of hypermineralized tissue, the volume of tissue with density equivalent to that of 
normal cortical bone, and the maximum density.  Hypermineralized tissue was defined as 
material that exceeded the maximum density of cortical bone in the spine of wild-type 
mice within a specified age group. In the present study, we defined threshold values of 
610, 630 and 710 mg HA cm
-3
 for maximum spinal bone density in animals of ages 2, 4 
and 6 (or greater) months, respectively. Previous studies have reported a similar increase 
in murine cortical bone density during the first 24 weeks of postnatal development (38). 
Normal density tissue was defined as material that exceeded a minimum threshold (126 
mg HA cm
-3
), but fell below the maximum thresholds defined above. Volume 
measurements are reported in cubic millimeters (mm
3
), representing the summation of all 
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the volume elements that fell within the defined range of mineral density. Additionally, 
the maximum mineralized tissue density within the volume of interest was reported. 
Nonlinear least squares fits were obtained using GraphPad Prism; data for volume of 
hypermineralized lesions were fit with an exponential growth equation, and data for the 
volume of normal bone and maximum density values were fit with one-phase association 
equations. 
 
2.3.4 Scanning electron microscopy and energy-dispersive X-ray spectroscopy  
 Scanning electron microscopy (SEM) imaging and energy-dispersive X-ray 
spectroscopy (EDX) microanalyses were performed based on previous reports (39) using 
a LEO 1540XB FIB/SEM instrument (Carl Zeiss, Oberkochen, Germany) and X-ray 
analysis system (Oxford Instruments, Oxford, UK) at the Western Nanofabrication 
Facility (The University of Western Ontario). Prior to SEM imaging, dried samples were 
coated with 5 nm of osmium using a plasma coater (OPC-80T; Filgen Inc.). EDX spectra 
were collected from bone and mineralized lesions identified by electron backscatter 
imaging at 20 keV beam energy. Elemental analysis of the EDX spectra was performed 
using INCA software (Oxford instruments), including background correction and fitting 
of all peaks. 
 
2.3.5 Histology 
 Formalin-fixed tissue samples were decalcified with Shandon TBD-2 Decalcifier 
(Thermo Scientific, Nepean, ON Canada) at a ratio of 10:1 (fluid:tissue) for 5 days with 
gentle rocking. Following standard histological processing, decalcified samples were 
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embedded in paraffin and 5 µm-thick serial sections were cut. Tissues were sectioned in 
the coronal plane, mounted on glass slides and baked for 48 hours at 45°C. Slides were 
stained with haematoxylin and eosin (H&E) and images were acquired using a Leica 
DM1000 microscope.   
For visualization of cell nuclei, sections described above were dewaxed in xylene 
and rehydrated by successive immersion in descending concentrations of ethanol. 
Mounting was performed with VECTASHIELD Mounting Medium with 4',6-diamidino-
2-phenylindole (DAPI) (Burlingame, CA) and images were captured using a Leica 
DMI6000B microscope. 
 
2.3.6 Blood chemistry 
High-performance liquid chromatography (HPLC) was used to analyze plasma for 
levels of adenosine and adenosine metabolites to determine the functional consequence of 
loss of ENT1. At 2 months of age, mice were anesthetized with pentobarbital. Blood was 
collected by cardiac puncture into a syringe containing NaCl (118 mM), KCl (5 mM), 
EDTA (13.2 mM), 5-iodotubercidin (10 µM) to inhibit adenosine kinase, erythro-9-(2-
hydroxy-3-nonyl)adenine hydrochloride (EHNA, 100 µM) to inhibit adenosine 
deaminase and dilazep (10 µM) to inhibit adenosine transport (40). Plasma was isolated 
by sedimentation at 3,000g for 10 minutes at 4°C. Plasma was applied to a 10-kDa cutoff 
ultra-filtration column and sedimented at 14,000g for 15 minutes at 4°C. Filtered plasma 
was analyzed on an Onyx monolithic C18 column as described (41), using a Hewlett 
Packard 1090 LC with UV detector. Adenosine was detected at 260 nm and adenosine 
metabolites at 250 nm. 
51 
 
 To screen for systemic changes resulting from loss of ENT1 function, serum 
chemistry was performed using established panels of clinical chemistry parameters. At 2 
months of age, mice were anesthetized with pentobarbital and blood was collected by 
cardiac puncture. Blood was allowed to coagulate at room temperature for 30 minutes. 
Samples were then sedimented at 3,000g for 10 minutes at 4°C and the serum supernatant 
was transferred to a fresh tube and frozen at -80°C. Chemical and biochemical analyses 
were performed by the Centre for Modeling Human Disease at the Toronto Centre for 
Phenogenomics (Toronto, Canada).  
 To assay plasma levels of inorganic pyrophosphate (PPi), mice were anesthetized 
with pentobarbital and blood was collected by cardiac puncture. Samples were transferred 
to microfuge tubes containing heparin (5 USP units/mL of blood) and plasma was 
isolated by sedimentation at 3,000g for 10 minutes at 4°C. Plasma was applied to 10-kDa 
cutoff ultra-filtration spin columns and sedimented at 14,000g for 20 minutes at 4ºC. A 
fluorometric PPi assay kit (ab112155; Abcam, Cambridge, MA, USA) was first validated 
using plasma samples from wild-type mice, plasma supplemented with a saturating 
concentration of PPi (30 µM) in the presence or absence of inorganic pyrophosphatase 
(0.0012 units/µL sample; Sigma) (Fig. 2.1). Plasma samples were isolated from 2-month-
old wild-type and ENT1
-/- 
mice (n=6 mice for each genotype) and analyzed according to 
the manufacturer’s protocol with an incubation time of 20 minutes. Fluorescence was 
measured at excitation and emission wavelength of 316 and 456 nm, respectively, using a 
SpectraMax M5 microplate reader (Molecular Devices) with Softmax Pro v5 software. 
Values were interpolated using linear regression. Background levels of plasma 
autofluorescence were negligible. 
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Figure 2.1: Validation of inorganic pyrophosphate assay. 
The fluorometric Pyrophosphate Assay Kit was validated using pooled plasma obtained 
from wild-type mice. To reduce protein concentration, plasma was applied to a 10 kDa 
cutoff ultra-filtration columns. Pyrophosphate was measured in: i) filtered plasma; ii) 
filtered plasma supplemented with a saturating concentration of exogenous 
pyrophosphate (PPi, 30 µM); and iii) filtered plasma supplemented with PPi (30 µM) and 
pyrophosphatase (PPase, 0.0012 units/µL sample). Samples were analyzed according to 
the manufacturer’s protocol with an incubation time of 20 min. Exogenous 
pyrophosphate caused a significant increase in the signal (to maximal detectable levels). 
Moreover, incubation with pyrophosphatase significantly diminished the pyrophosphate-
induced increase in signal intensity. Taken together, these data establish that the kit 
effectively detects pyrophosphate in ultra-filtered plasma. Assay was performed using 4 
replicate samples for each condition. Data are presented as means ± SEM, n=4. Bars 
labeled with the same lower case letter are not significantly different, based on one-way 
analysis of variance followed by a Tukey multiple comparisons test.   
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2.3.7 Quantitative real-time RT-PCR 
At 6 months of age, littermate-paired wild-type and ENT1
-/-
 mice (n=8 for each 
genotype) were dissected to isolate intervertebral discs (IVDs) inclusive of annulus 
fibrosus, nucleus pulposus, and cartilage endplates. IVDs from each animal were 
separated according to anatomical location as cervical-thoracic, lumbar, or caudal.  
Tissues were placed directly in 1 mL of TRIzol Reagent (Life Technologies, Wilmington, 
DE) and homogenized using a PRO250 Polytron benchtop homogenizer (PRO Scientific, 
Oxford, CT). Total RNA was extracted according to the manufacturer’s protocol and 
quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Mississauga, 
ON). For each sample, 1 µg RNA was reverse transcribed into cDNA using Superscript II 
Reverse Transcriptase (Life Technologies). Gene expression patterns were determined by 
real-time PCR using the Bio-Rad CFX384 system. PCR reactions were run in triplicate, 
using 25 µM forward and reverse primers (primer sequences in Table 2.1) with 2X 
SsoFast EvaGreen Supermix (Bio-Rad, Mississauga, ON). The PCR program consisted 
of the following: initial 3 min at 95
o
C for denaturing; 95
o
C for 10 s denaturing; 30 s 
annealing/elongation (temperatures provided in Table 2.1), for a total of 40 cycles. Gene 
transcript levels were determined relative to a six-point calibration curve made from 
cDNA generated from heart, brain, kidney, muscle, intervertebral disc, and calvarial 
RNA (from wild-type mice). The starting concentration of the cDNA standard (83 – 136 
ng/µl) was inputted into the Bio-Rad CFX Manager 2.0 software to generate the standard 
curve (1/5 serial dilution). Values for gene transcript levels are expressed relative to the 
calibration curve in ng/µl. Standard curves were generated to control for primer 
efficiency and specificity of primers was determined by melt curve analysis (0.5C/5 s).  
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Table 2.1: Real-time PCR Primer Sequences 
 
Gene Name Primer Sequence (5’ to 3’) Optimal 
Temperature (
o
C) 
Adora3 Fwd – ACTTCTATGCCTGCCTTTTCATGT 
Rev – AACCGTTCTATATCTGACTGTCAGCTT 
56 
Ank 
 
Fwd – CCCTGATAGCCTACAGTGACTTAGG 
Rev – GAAGGCAGCGAGATACAGGAA 
56 
Alpl Fwd - CCAACTCTTTTGTGCCAGAGAA 
Rev – GGCTACATTGGTGTTGAGCTTTT 
60 
Enpp1 Fwd - CAAAACCCACAATGACTGTTGC 
Rev – CTGGACACTCCGGGGTATCG 
56 
ENT1 Fwd - CAAGTATTTCACAAACCGCCTGGAC 
Rev – GAAACGAGTTGAGGCAGGTGAAGAC 
56 
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2.4 Results 
2.4.1 Ectopic mineralization in ENT1
-/-
 mice 
 Previous studies reported that ENT1
-/-
 mice are phenotypically normal, with only 
a modest decrease (~10%) in body weight compared with that of wild-type littermates 
(33). At young ages, open-field locomotor activity in ENT1
-/-
 and wild-type mice does not 
differ. Moreover, there is no significant difference in spontaneous mortality rates up to 6 
months of age. To date, there have been no reports of phenotypic changes in skeletal 
tissues related to mineralization (33,34,42,43); however, all reported studies were 
conducted on mice less than 4 months of age.  
In the present study, we noted that the spines of 6-month-old ENT1
-/-
 mice were 
extremely rigid. At 8 months, ENT1
-/-
 mice demonstrated decreased hind limb mobility 
that progressed to hind limb paralysis by 12 to 17 months of age. Postmortem analysis of 
a 17-month-old ENT1
-/-
 mouse revealed hard, chalky white lesions protruding ventrally 
from the thoracic spine (Fig. 2.2A). µCT images revealed large radio-opaque lesions at 
distinct foci in the cervical and upper thoracic regions of ENT1
-/-
 mice, localized to 
paraspinal and intervertebral tissues and protruding in some cases into the spinal canal 
(Fig. 2.2B). Histological examination identified large accumulations of amorphous 
material (Fig. 2.2C) localized to the intervertebral discs (upper panel) and paraspinal 
tissues associated with the spinous processes (lower panel). The presence of calcified 
lesions within the spinal canal, impinging on the spinal cord, was consistent with the 
decreased mobility and paralysis observed in ENT1
-/-
 mice.  
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Figure 2.2: Ectopic mineralization of spinal tissues in ENT1
-/-
 mice.  
(A) Gross appearance of ventral aspect of the thoracic spine from 17-month-old wild-type 
(WT) and ENT1
-/-
 mice. Mineralized lesions protrude from intervertebral spaces, 
associated with rib entheses. Lesions demonstrated hard, chalky consistency and were 
whitish in colour. (B) Maximum intensity projection of µCT images showing the lateral 
aspect of the cervical and thoracic spine of 17-month-old WT and ENT1
-/-
 mice. Ectopic 
radio-opaque material is evident in paraspinal and intervertebral regions of the spine 
(arrows) extending into the spinal canal (SC). (C) Histological sections of decalcified 
spinal tissues from 17-month-old ENT1
-/-
 mouse (spinal column and spinal cord) stained 
with H&E. Mineralized lesion (outlined in black) can be seen protruding into the spinal 
canal and impinging on the spinal cord. Images in B and C are oriented with ventral to the 
left. Scale bars represent 200 μm.   
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2.4.2 Time course of phenotype development 
 
 µCT imaging was employed to assess the development and extent of ectopic 
mineralization in ENT1
-/-
 mice over time (Fig. 2.3A).  Images were scored for severity, 
based on the percentage of affected sites within the spine (intervertebral discs, and 
associated paraspinal ligaments and entheses) in each anatomical region (Fig. 2.3B). 
Ectopic mineralization of spinal tissues was not evident in wild-type animals at any time 
point (Fig. 2.3A), or in ENT1
-/-
 mice at 1 month of age (not shown).  
Ectopic mineralization in ENT1
-/-
 mice proceeded temporally in a consistent 
anatomical pattern. At 2 months of age, maximum intensity projection (MIP) images 
revealed radio-opaque material in the paraspinal tissues of the cervical spine and the rib 
entheses of the upper thoracic spine (Fig. 2.3, top panels). At this age, there was no 
detectable involvement of intervertebral discs.  
With advancing age, accumulation of ectopic mineral progressed caudally, with 
involvement of the lumbar spine at 6 months (Fig. 2.3, middle panels). In addition to 
paraspinal tissues and rib entheses, lesions were observed within the intervertebral spaces 
at 6 months in both the thoracic and lumbar spine. At this time point, lesions involved 60 
to 90% of the cervical spine and 30 to 60% of the thoracic spine. Interestingly, lesions did 
not progress caudally in a uniform manner. Following involvement of the cervical and 
upper thoracic spine, lesion formation initially bypassed the mid-region of the thoracic 
spine and first appeared specifically in thoracic vertebrae T11-T12 (Fig. 2.3A, asterisk). At 
greater ages, lesions developed in the intervening mid-region of the thoracic spine.   
By 12 months of age, ectopic mineralization was detected in >60% of the 
cervical, thoracic and lumbar regions of the spine, as well as >30% of intervertebral discs  
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Figure 2.3: Temporal progression of ectopic mineralization in ENT1
-/-
 mice.  
(A) Lateral and antero-posterior maximum intensity projections of micro-CT images of 
wild-type (WT) and ENT1
-/-
 mice at 2, 6 or 12+ months of age. Ectopic radio-opaque 
material was observed in paraspinal tissues of the cervical spine at 2 months of age (top 
panel, white arrows).  By 6 months of age, lesions were detected in the cervical (white 
arrows), thoracic and lumbar spine in paraspinal ligaments, rib entheses and 
intervertebral discs (middle panel). At 6 months, lesions involved the upper thoracic 
spine, but appeared to bypass the mid-region of the thoracic spine to specifically affect 
sites in the vicinity of thoracic vertebrae T11-T12 (indicated by white asterisk). By 12 
months of age, lesions involved virtually the entire cervical, thoracic and lumbar spine, 
and were detectable in the intervertebral discs of the caudal spine (lower panel). Note that 
the focal hyperintensities observed in the abdomen result from high-density material in 
the animal chow; these bright spots do not represent ectopic calcifications. (B) The 
percentage of sites affected by mineralization in each anatomical region of the spine was 
scored in ENT1
-/-
 mice at 2, 6 or 12+ months of age. A severity score of 0 reflects no 
detectable mineralized lesions, 1 indicates lesions involving 0 to 30% of sites within the 
anatomical region, 2 indicates lesions involving 30 to 60% of sites, 3 indicates lesions 
involving 60 to 90% of sites, and a score of 4 indicates lesions involving 90 to 100% of 
sites. The symbols represent scores for individual mice and bars represent the mean. 
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of the caudal spine (Fig. 2.3, lower panel).  In addition, there was notable decrease in 
kyphosis between 6 and 12 months of age in ENT1
-/-
 mice compared to wild-type (Fig. 
2.3A, lower panel). No evidence of ectopic mineralization was detected in the vasculature 
of ENT1
-/-
 mice at any time point examined by µCT.   
 To examine the consequence of ENT1 haploinsufficiency, 6-month-old 
heterozygous ENT1
+/-
 mice were examined by µCT (Fig. 2.4). In contrast to ENT1
-/-
 
mice, heterozygous animals did not demonstrate ectopic mineral formation in paraspinal 
tissues, rib entheses, or intervertebral discs. Moreover, the loss of kyphosis observed in 
knockout animals was not apparent; ENT1 heterozygous animals were indistinguishable 
from wild- type controls. 
 
2.4.3 Density and elemental composition of ectopic lesions 
Mineralized tissue density of wild-type
 
and ENT1
-/-
 mice at different ages was 
quantified from µCT data. The region of interest for these analyses consisted of the 
cervical to lumbar spine, rib cage, and sternum. Hypermineralized tissue was detected in 
paraspinal and intervertebral tissues of the spine, as well as the sternocostal articulations 
(highlighted in red in Fig. 2.5A). Quantification revealed that the volume of 
hypermineralized tissue grew exponentially with age in the ENT1
-/-
 mice, whereas there 
was little hypermineralized tissue detectable in wild-type mice at any age (Fig. 2.5B).  
We also quantified the volume of mineralized tissue with density equivalent to that of 
normal cortical bone (Fig. 2.5C). Whereas the wild-type animals appeared to reach a 
plateau of approximately 355 mm
3
 by day 200 (reflecting bone growth), ENT1
-/-
 mice 
reached a plateau of 552 mm
3
 by day 400 (reflecting both bone growth and accumulation   
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Figure 2.4: Micro-CT images of wild-type, heterozygous, and ENT1
-/-
 mice.  
Images are lateral (top panel) and antero-posterior (bottom panel) maximum intensity 
projections of wild-type (WT), heterozygous (ENT1
+/-
), and ENT1
-/-
 mice at 6 months of 
age. No ectopic mineral was observed in the WT or heterozygous mice. Ectopic radio-
opaque material was observed in ENT1
-/-
 mice; lesions were detected in the paraspinal 
ligaments, rib entheses and intervertebral discs of the cervical, thoracic, and lumbar 
regions (white arrows). Images are representative of 3 animals of each genotype.  
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Figure 2.5: Quantification of the volume and density of mineralized material in 
wild-type and ENT1
-/-
 mice over time.   
(A) Lateral maximum intensity projections of the µCT images of a wild-type (WT) and 
an ENT1
-/-
 mouse at 17 months of age. The region of interest for these analyses was 
restricted to the cervical, thoracic and lumbar spine, rib cage and sternum. The regions 
highlighted in red represent hypermineralized tissue within the region of interest. (B) The 
volume of hypermineralized tissue grew exponentially with age in the ENT1
-/-
 mice. (C) 
ENT1
-/-
 mice also showed increased volume of mineralized tissue with normal bone 
density (consisting of both bone and ectopic calcifications). Whereas the wild-type 
animals appeared to reach a plateau (of approximately 355 mm
3
 by day 200), the ENT1
-/-
 
mice reached a plateau (552 mm
3
) by day 400. (D) Likewise, the maximum mineral 
density of the wild-type mice reached a plateau before an age of 200 days, whereas that 
of the ENT1
-/- 
mice continued to increase past day 400.
 
For B-D, the symbols represent 
µCT-derived parameters for individual mice and the lines represent the non-linear fits.   
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of ectopic mineral). Likewise, the maximum mineral density of the wild-type mice 
reached a plateau before an age of 200 days, whereas that of the ENT1
-/- 
mice continued 
to increase past day 400 (Fig. 2.5D), reflecting hypermineralization of the ectopic lesions.
 
 
A summary and statistical analysis of these data is presented in Table 2.2. From 2 
to 17 months of age, the volume of bone in wild-type mice increased from 259 to 356 
mm
3
 with only about 0.5 mm
3
 appearing hypermineralized (regardless of age) according 
to the thresholds used. The mineralized tissue volume of ENT1
-/- 
mice was similar to that 
of wild-type controls up to 6 months of age. In contrast, 12-to 17-month-old ENT1
-/-
 mice 
had a significantly greater volume of mineralized tissue than the equivalent age of wild-
type mice (527 versus 356 mm
3
). In addition, the ENT1
-/-
 mice had a significantly greater 
volume of hypermineralized tissue than wild-type mice between 12 to 17 months old (16 
versus 0.5 mm
3
), and the maximum mineral density was significantly greater in ENT1
-/-
 
mice than wild-type controls at both 6 and 12 month of age. Note that, whereas the 
maximum mineral density observed in ENT1
-/-
 mice (1044 mg HA cm
-3
) does not exceed 
the typical value for fully mineralized cortical bone (approximately 1050 mg HA cm
-3
), it 
is significantly greater than the mineral density of cortical bone observed in the spine of 
wild-type littermates (744 mg HA cm
-3
). 
Samples from wild-type and ENT1
-/-
 mice at 6 months of age were analyzed by 
EDX to determine the elemental content of both cortical bone and mineralized lesions. 
Mineralized lesions appeared by SEM as a disordered amorphous material (Fig. 2.6A, B) 
and EDX revealed a high content of calcium and phosphorus (Fig. 2.6C).The mean 
elemental content of bone and lesions is displayed as percent atomic ratio in Table 2.3.  
The vertebral bone from ENT1
-/-
 mice was not significantly different from that of wild- 
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Table 2.2: Mineralized Tissue Density in ENT1
-/-
 and Wild-type Mice 
 
µCT-derived values for the volume of normal and hypermineralized tissue and the 
maximum density in ENT1
-/-
 and wild-type mice. Data are means ± SD. Differences were 
evaluated by two-way analysis of variance (ANOVA) followed by a Bonferroni multiple 
comparison test. 
ENT1 = equilibrative nucleoside transporter 1; HA = hydroxyapatite. 
Significantly different from wild type: * p < 0.05, ** p < 0.001. 
 
 
 
 
 
 
 
 
 
 
  
64 
 
 
Figure 2.6: Scanning electron microscopy (SEM) and elemental analysis of 
mineralized lesions by energy dispersive X-ray spectroscopy (EDX).   
(A, B) SEM of mineralized lesion in ENT1
-/-
 mouse at 6 months of age. Mineralized 
lesions appeared as a disordered amorphous material. Representative areas (2 or 3 per 
sample) were selected and probed by EDX for calcium (Ca), phosphorous (P), carbon (C) 
and oxygen (O). Magnesium (Mg) and sodium (Na) were detected in some, but not all, 
samples and hence were not included in the quantitative analysis shown in Table 2.3.  
(C) A representative EDX spectrum (from the region highlighted in Panel A) is shown, 
revealing a high content of calcium and phosphorus. Images and spectrum are 
representative of lesion samples from 4 mice.     
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Table 2.3: Energy-Dispersive X-ray Spectroscopy  
Location Genotype 
% Atomic Ratio 
Carbon Oxygen Phosphorous Calcium Ca/P Ratio 
Vertebra WT 45.1 ± 4.8 34.0 ± 1.8 7.4 ± 0.7 12.7 ± 2.3 1.7 ± 0.1 
 ENT1-/- 45.6 ± 2.2 37.5 ± 0.9 6.8 ± 0.5 10.5 ± 0.6 1.6 ± 0.1 
Lesion ENT1-/- 37.6 ± 3.5 41.6 ± 2.3 8.7 ± 0.4* 13.3 ± 1.1* 1.5 ± 0.1 
 
Scanning electron microscopy was used to identify regions of vertebral cortical bone and 
ectopic mineralization (lesion) in samples isolated from 6-month-old WT and ENT1
-/-
 
mice. Energy-dispersive X-ray spectroscopy was then applied to these selected regions to 
obtain the % atomic ratios of the indicated elements. Data are mean ± SEM, n = 4.   
WT = wild-type; ENT1 = equilibrative nucleoside transporter 1. 
* Significant difference between lesion and ENT1
-/- 
vertebra (p < 0.05; Student’s t-test). 
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type mice in terms of elemental ratios. In contrast, ectopic mineralized lesions in ENT1
-/-
 
mice displayed higher levels of phosphorus and calcium relative to vertebral bone, 
consistent with the greater mineralized tissue density observed using µCT. The 
calcium/phosphorus ratio was similar in all samples.    
 
2.4.4 Histological appearance of mineralized lesions 
 We first assessed the intervertebral disc regions of wild-type and ENT1
-/-
 mice 
between 12 and 17 months of age. Decalcified sections stained with H&E revealed the 
presence in ENT1
-/-
 mice of large accumulations of amorphous, eosinophilic acellular 
material suggestive of niduses of mineralization in the cervical, thoracic, lumbar and 
caudal regions (Fig. 2.7). Interestingly, within the intervertebral disc, lesions appeared to 
be localized within the annulus fibrosus, leading to lateral compression of the nucleus 
pulposus and extensive bulging of the annulus fibrosus out of the intervertebral space 
(Fig. 2.7, right panels). There was no evidence that lesions were associated with 
inflammation or increased vascularization. Since the sacral intervertebral discs undergo 
progressive fusion with the onset of skeletal maturity in mice, this region was not 
examined for ectopic mineralization.  
Lesions were also detected in the sternocostal region of ENT1
-/-
 mice between 12 
and 17 months of age, by both µCT and histology (Figs. 2.3, 2.5A and Fig. 2.8A). In this 
region, extensive ectopic mineral was detected within the connective tissue of the 
sternocostal articulations, leading to deformation of the sternum. In contrast, examination 
of appendicular joints revealed no aberrant morphology or evidence of ectopic 
mineralization (Fig. 2.8B-E) establishing that lesions are specifically associated with the   
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Figure 2.7: Histological appearance of spinal tissues in cervical (A), thoracic (B), 
lumbar (C) and caudal (D) spines of 12+ month old wild-type (WT) and ENT1
-/-
 
mice.  
Vertebral structures are indicated in panel A: the intervertebral disc (IVD) is formed by 
the annulus fibrosus outlined in yellow and nucleus pulposus outlined in red, which are 
located between adjacent vertebral bones (VB). The spines of ENT1
-/- 
mice show 
irregular lesions within the annulus fibrosus of the intervertebral disc. Lesions are 
encapsulated by layers of fibrocartilaginous cells. Lesions are outlined with black dashed 
lines and are shown at higher magnification in the panels to the right. Samples were 
sectioned in the coronal plane and stained with haematoxylin and eosin (H&E). Images 
are oriented with rostral at the top and are representative of 3 animals of each genotype 
12-17 months of age. Scale bars represent 200 μm. 
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Figure 2.8: Histological appearance of sternocostal (A), humeroulnar (B), 
tibiofemoral (C), radiocarpal (D) and talocrural (E) joints in 12+ month-old wild-
type (WT) and ENT1
-/-
 mice (arrows indicate joint spaces).  
In ENT1
-/-
 mice, sternocostal joints displayed lesions in fibrocartilaginous connective 
tissues, similar to those seen in the spine.  In contrast, the appendicular joints appeared to 
be unaffected. Lesion in panel A is outlined with black dashed line and tissues are shown 
at higher magnification in the panel to the right. Samples were sectioned in the coronal 
plane and stained with haematoxylin and eosin (H&E). Images are representative of 3 
animals of each genotype 12-17 months of age. Scale bars represent 200 μm. 
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axial skeleton. 
Comparison of histological sections of spinal tissues from wild-type and ENT1
-/-
 
mice at 6 months of age revealed further insights into the development of lesions. Within 
the cervical spine of 6-month-old ENT1
-/-
 mice, large lesions were associated with the 
paraspinal ligaments, but no distinct lesions were detected within the intervertebral discs 
in this region (Fig. 2.9A). However, the outer annulus fibrosus of the intervertebral discs 
did appear altered, with regions of metaplasia and disruption of normal tissue architecture 
(Fig. 2.9A, arrowhead). Within the thoracic spine of 6-month-old ENT1
-/-
 mice, extensive 
lesions were localized within: (1) the annulus fibrosus; (2) the fibrocartilaginous tissue of 
the posterior paraspinal ligaments; and (3) the fibrocartilaginous tissue of the rib entheses 
(Fig. 2.9B). In the lumbar spine of 6-month-old ENT1
-/-
 mice, small lesions were detected 
within the annulus fibrosus, leading to disruption of intervertebral disc structure and 
displacement of the nucleus pulposus (Fig. 2.9C). At this time point, no changes were 
detected within the caudal spine. 
At 2 months of age, when ectopic mineral was first detected in ENT1
-/-
 mice by 
µCT, histological examination also demonstrated lesions within the paraspinal ligaments 
of the cervical spine (Fig. 2.10A). Interestingly, these lesions were associated with large 
regions of metaplasia, with a disruption of normal tissue architecture and increased 
cellularity (Fig 2.10A, arrowheads). In the upper thoracic spine, the mineralized lesions 
detected by µCT in ENT1
-/-
 mice were localized to the fibrocartilaginous structures of the 
paraspinal ligaments and rib entheses, within larger regions demonstrating evidence of 
hyperplasia and desmoplasia (Fig. 2.10B, arrowheads). At this time point, no lesions were 
detectable in intervertebral discs within any region of the spine. Early lesions evident at 2   
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Figure 2.9: Histological appearance of spinal tissues in cervical (A), thoracic (B) and 
lumbar (C) spine segments from 6-month-old wild-type (WT) and ENT1
-/-
 mice. 
Representative images demonstrate the location of lesions consisting of irregular 
accumulations of eosinophilic material in the intervertebral disc (IVD), paraspinal 
ligaments, and rib entheses in ENT1
-/-
 mice. Lesions are outlined with black dashed lines 
and tissues are shown at higher magnification in the panels to the right. Arrowhead in (A) 
indicates a nonmineralized region of metaplasia accompanied by disruption of normal 
tissue architecture in the annulus fibrosus of the IVD. Images are oriented with rostral at 
the top and are representative of 3 animals of each genotype. Scale bars represent 200 
μm. 
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Figure 2.10: Histological appearance of the intervertebral disc (IVD), paraspinal 
ligaments, and rib entheses in cervical (A) and thoracic (B) spine segments from 2-
month-old wild-type (WT) and ENT1
-/-
 mice. Lesions are outlined with black dashed 
lines and tissues are shown at higher magnification in the panels to the right. Arrowheads 
indicate regions demonstrating tissue metaplasia. (C) Serial sections of representative 
lesion localized to the paraspinal tissue of the thoracic spine of a 2-month-old ENT1
-/-
 
mouse stained with H&E (top panel) and DAPI (bottom panel). Cells with eosinophilic 
nuclei are detected in the transition zone (TZ) between normal fibrocartilaginous tissues 
and lesion. DAPI staining demonstrates that these cells retain an intact nuclear structure 
(arrows indicate individual cells). Images are oriented with rostral at the top and are 
representative of at least 3 ENT1
-/-
 animals. Scale bars represent 200 μm.  
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months of age were surrounded by a clearly demarcated transition zone (TZ; Fig. 2.10C). 
The periphery of this zone consisted of typical fibrocartilaginous tissue and, as expected, 
cells with basophilic nuclei that stained positively with DAPI (Fig. 2.10C, lower panels). 
However, the more central region of the transition zone was characterized by metaplasia, 
with cells displaying eosinophilic nuclei that stained positively with DAPI, revealing an 
intact nuclear structure. The TZ surrounded the presumptive mineralized lesion, which 
contained large accumulations of amorphous matrix and necrotic cell debris. There was 
no evidence of apoptotic nuclei within the lesion or TZ. 
 
2.4.5. Differences in blood chemistry and gene expression associated with the  
ENT1
-/- 
phenotype 
 Blood plasma or serum from 2-month-old wild-type
 
and ENT1
-/-
 mice was 
analyzed for components related to mineralization as well as adenosine and adenosine 
metabolites (Table 2.4). HPLC analysis of plasma showed 2.8-fold greater adenosine 
levels in ENT1
-/-
 than wild-type mice. In contrast, there were no significant differences in 
levels of the adenosine metabolites xanthine and uric acid, arguing against the possibility 
that ectopic lesions involved deposition of monosodium urate crystals. Importantly, 
serum levels of alkaline phosphatase, calcium, phosphate, and magnesium were not 
significantly different in ENT1
-/-
 and wild-type mice. On the other hand, quantification of 
plasma PPi levels revealed 3.4 ± 1.0-fold greater levels in ENT1
-/-
 mice than in wild-type 
controls (n=6 two-month-old mice for each genotype, p < 0.05). 
  Given this alteration in PPi levels, we interrogated the expression of genes 
associated with pyrophosphate metabolism in intervertebral disc tissues isolated from 
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Table 2.4: Blood Chemistry 
 
 
Wild-type 
(n = 4) 
ENT1
-/-
 
(n = 5) 
Adenosine (µM) 2.2 ± 0.4 6.2 ± 1.4* 
Xanthine (µM) 4.3 ± 1.5 5.2 ± 2.4 
Uric acid (µM) 163 ± 23 176 ± 14 
ALP (IU/L) 97 ± 9 109 ± 10 
Ca (mM) 2.30 ± 0.03 2.31 ± 0.02 
Mg (mM) 1.26 ± 0.04 1.30 ± 0.08 
Pi (mM) 3.1 ± 0.3 3.7 ± 0.4 
  
 
Data are means ± SEM. Serum was obtained 
from wild-type and ENT1
-/-
 mice at two 
months of age.  
ALP = total alkaline phosphatase; ENT1 = 
equilibrative nucleoside transporter 1; Pi = 
inorganic phosphate.  
* Significantly different from wild-type (p < 
0.05, Student’s t-test).  
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Figure 2.11: Gene expression analysis of intervertebral disc tissues isolated from 6-
month-old wild-type and ENT1
-/-
 mice.  
Real-time PCR analysis of genes associated with PPi metabolism and tissue 
mineralization revealed significant reductions in the expression of (A) Enpp1, (B) Ank, 
and (C) Alpl in ENT1
-/-
 mice compared to wild-type controls. (D) In contrast, there was 
no significant difference in the expression of the adenosine A3 receptor (Adora3), 
indicating specificity of changes in gene expression. (E) Real-time PCR analysis of ENT1 
expression revealed no significant differences between anatomical regions of the spine in 
wild-type mice. ** Significantly different from wild-type (p < 0.01, Student’s t-test). 
A 
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B 
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ENT1
-/-
 and wild-type littermate control mice at 6 months of age. Real-time PCR analysis 
demonstrated a significant decrease in the expression of ectonucleotide pyrophosphatase/ 
phosphodiesterase 1 (Enpp1; Fig. 2.11A), Ank (a putative PPi transporter) (Fig. 2.11B), 
and tissue nonspecific alkaline phosphatase (Alpl; Fig. 2.11C) in ENT1
-/-
 mice. In 
contrast, no significant difference was detected in the expression of unrelated genes 
including the adenosine A3 receptor (Adora3; Fig. 2.11D) in ENT1
-/-
 and wild-type mice, 
indicating specificity. 
To determine if the specific anatomical pattern of ectopic mineralization was 
influenced by endogenous levels of ENT1, expression was assessed in 6-month-old wild-
type mice. No differences were detected in ENT1 transcript levels in intervertebral disc 
tissues isolated from cervical-thoracic, lumbar, or caudal regions of the spinal column 
(Fig. 2.11E).  
 
2.5 Discussion  
This is the first report of a role for ENT1 in regulating biomineralization. We 
discovered that ENT1
-/- 
mice develop ectopic mineralization with distribution restricted to 
the fibrous connective tissues of the spine and sternum. In the spine, pathological 
mineralization begins in the paraspinal fibrocartilaginous tissues and progresses to 
involve the annulus fibrosus of intervertebral discs. Aberrant mineralization is first 
observed in ENT1
-/-
 mice between 6 and 8 weeks of age in the paraspinal connective 
tissues of the cervical vertebrae. With advancing age, lesions increase in severity and 
progress to other regions of the spine, with ectopic mineralization eventually involving 
the thoracic, lumbar and caudal spine, as well as the sternocostal articulations.  
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ENT1
-/-
 mice were first used to investigate the role of adenosine transport in the 
central nervous system pathways regulating alcohol consumption (33). In that study, male 
mice were examined at approximately 10 weeks of age and appeared normal in their 
anatomy, physiology, mortality rates and consumption of water. However, ENT1
-/-
 mice 
consumed twice as much alcohol compared to wild-type controls. This behavior was 
associated with a decrease in endogenous adenosine tone, which was not due to loss of A1 
receptors or decreases in A1 receptor affinity. ENT1
-/-
 mice have also been shown to 
exhibit reduced anxiety-like behaviors (44). Levels of endogenous extracellular 
adenosine were not reported in these studies.   
More recently, ENT1-null mice have been used to investigate the role of this 
transporter in the cardiovascular system. Microvascular endothelial cells isolated from 
ENT1
-/-
 mice have enhanced expression of the A2A adenosine receptor and adenosine 
deaminase (34). Cardiomyocytes and microvascular endothelial cells from ENT1
-/-
 mice 
are relatively resistant to ischemic insult and ENT1
-/-
 mice show decreased heart damage 
in response to ischemia and hypoxia (45). Furthermore, loss of ENT1 protects against 
ischemic acute kidney injury through control of postischemic renal perfusion (46). 
Overall, these studies point to a cardioprotective role of ENT1. However, it is unlikely 
that changes in the nervous and cardiovascular systems give rise to ectopic mineralization 
in ENT1
-/-
 mice, especially of the inner annulus fibrosus, which is considered an 
avascular and aneural tissue (47,48). 
In the present study, we found that plasma adenosine concentrations are 
significantly elevated in the ENT1
-/- 
mice compared to wild-type littermates. This finding 
is in keeping with differences reported (42). The greater plasma concentration of 
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adenosine in ENT1
-/- 
mice likely reflects extracellular accumulation of adenosine due to 
lack of uptake by cells that normally express ENT1, one of the primary uptake pathways 
for adenosine (32,49). The role of elevated extracellular adenosine in the formation of 
abnormal mineral deposits in fibrocartilaginous tissues remains to be explored, but may 
involve local changes in adenosine receptor signaling.  
In this regard, recent advances point to a critical role for purine metabolism and 
signaling in the regulation of biomineralization and in diseases associated with either 
insufficient or ectopic mineralization (26-31). Once released by the cell, extracellular 
adenosine triphosphate (ATP) is sequentially metabolised by cell-surface enzymes, 
leading first to the production of PPi and adenosine monophosphate (AMP), which in turn 
are converted to inorganic phosphate and adenosine. Ectonucleotide pyrophosphatase/ 
phosphodiesterase 1 (Enpp1) is responsible for the first step in this process, and the 
release of PPi has been shown to inhibit ectopic calcification in soft tissues (50). 
Interestingly, we show that ENT1-null mice demonstrate significant downregulation of 
Enpp1 expression in intervertebral disc tissues relative to wild-type littermate controls. 
These findings are in keeping with the reported association between mutations in the 
gene encoding Enpp1 and hypermineralization disorders such as idiopathic infantile 
calcification (26) and OPLL (27). Furthermore, Enpp1
-/-
 mice display soft tissue 
mineralization in the Achilles tendon, paraspinal ligaments and intervertebral discs, as 
well as hyperostosis of peripheral joints and calcification of articular cartilage (51). 
However, elements of the appendicular skeleton are not affected in ENT1
-/-
 mice; changes 
are limited to fibrocartilaginous tissues of the axial skeleton.   
We also observed a significant decrease in Ank expression in the intervertebral 
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discs of ENT1
-/-
 mice. Ank is a transmembrane protein that is thought to mediate PPi 
transport. In mice, loss-of-function mutations of Ank lead to arthritis, ectopic crystal 
formation and generalized joint fusion (52), whereas, in humans, dominant mutations are 
associated with craniometaphyseal dysplasia (53,54) and familial chondrocalcinosis 
(55,56). Thus, like Enpp1, decreased Ank expression in the spinal tissues of ENT1
-/- 
mice 
would be expected to further suppress extracellular PPi levels, permitting the formation of 
ectopic mineral deposits.   
Unexpectedly, expression of Alpl was also found to be decreased in the 
intervertebral discs of ENT1-null mice. Alpl encodes tissue-nonspecific alkaline 
phosphatase, which is responsible for the hydrolysis PPi (51), and Alpl expression has 
been shown previously to be regulated by extracellular adenosine (28). In humans, 
disruption of ALPL causes hypophosphatasia, characterized by skeletal 
hypomineralization (57) and presumably a result of excessive accumulation of PPi. Thus, 
decreased Alpl expression in the spinal tissues of ENT1
-/- 
mice would be expected to 
increase extracellular PPi levels, counteracting the decrease in PPi arising from changes in 
Enpp1 and Ank expression. Moreover, it is conceivable that a generalized decrease in 
Alpl expression could account for the increase in plasma PPi that we observed in ENT1
-/-
 
mice.  
Adenosine and ATP can regulate cell behaviour and gene expression through cell 
surface receptors – the adenosine receptor family (58) and the P2 family of nucleotide 
receptors (59,60), respectively. Adenosine increases intracellular cyclic AMP (cAMP) 
levels via its A2A and A2B receptor subtypes. cAMP has been shown to induce abnormal 
calcification of vascular smooth muscle cells via a mechanism involving reduction in 
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extracellular PPi accumulation (61,62). In addition, activation of the P2X7 subtype of 
ATP receptors promotes bone formation and mineralization (27,63).  
Taken together, our data suggest that disruption of adenosine signaling and PPi 
metabolism in ENT1
-/-
 mice is associated with disease onset and progression. Although 
there are no reported associations between mutations in the gene encoding ENT1 in 
humans and DISH, the high incidence of this disease in the human population argues 
against an underlying single gene defect. However, disruption of adenosine or PPi 
metabolism could result from alterations in the function of one or more regulatory or 
metabolic proteins – either through genetic defects or as a consequence of cell aging. 
In ENT1
-/- 
mice, the only location outside of the spine that exhibited ectopic 
mineralization was the sternocostal region. This distinct anatomical pattern of mineral 
deposition in ENT1
-/- 
mice suggests some common element in spinal and sternal 
fibrocartilaginous tissues makes them susceptible to ectopic mineralization in the absence 
of ENT1. Relatively scant vascular perfusion of the affected fibrocartilaginous tissues 
could lessen the clearance of extracellular adenosine, giving rise to sustained adenosine 
signaling which may in turn lead to deregulation of PPi metabolism.  
The spatial and temporal pattern of ectopic mineralization observed in the ENT1
-/-
 
mice, along with the absence of inflammation in affected tissues, resemble characteristics 
of diffuse idiopathic skeletal hyperostosis (DISH) in humans. DISH affects about 20% of 
the male population over the age of 55, with a slightly lower prevalence in women (35).  
Similarly, in ENT1
-/-
 mice, lesions developed gradually over time with functional 
impairments noticeable by 8 months of age. Similar to DISH in humans, which is often 
first diagnosed in the cervical or thoracic spine (64), lesions in ENT1
-/-
 mice began in the 
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cervicothoracic spine and spread caudally. Moreover, sternal involvement is also noted in 
DISH patients (65). On the other hand, extra-axial calcifications are present in some 
DISH patients, but were not detected by µCT or histology in ENT1
-/-
 mice. Interestingly, 
the reproducible pattern of mineral deposition observed in ENT1
-/-
 mice was not related to 
differences in endogenous ENT1 expression levels in the affected tissues. The factors 
contributing to the timing of mineral deposition at these sites remains an intriguing 
question for ongoing investigation. The radiographic appearance of DISH in humans 
bears striking resemblance to that of ectopic mineralization in ENT1
-/-
 mice. DISH is 
characterized by tortuous paravertebral calcifications generally anterior to the vertebral 
bodies (66). On gross examination the appearance is likened to that of candle wax 
dripping down the spine. This appearance is remarkably similar to that observed in the 
present study by µCT analysis of ENT1
-/-
 mice.   
In summary, this is the first report of a role for the primary membrane transporter 
for adenosine, ENT1, in regulating the calcification of soft tissues in mice. Disruption of 
purine homeostasis by removal of ENT1 leads to the ectopic mineralization of paraspinal 
ligaments and intervertebral discs in mice, resembling lesions seen in the human 
condition, DISH. Pathogenesis appears to be associated with both local and systemic 
changes in PPi homeostasis. The ENT1
-/- 
mouse may prove useful as a model for 
investigating the mechanisms underlying ectopic mineralization associated with DISH 
and for the evaluation of therapies for the prevention and reversal of DISH and associated 
pathologies.  
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3.1 Chapter Summary 
Recent studies have suggested a role for adenosine metabolism in the regulation 
of biomineralization. Equilibrative nucleoside transporter 1 (ENT1) is a membrane 
protein involved in the bi-directional transport of adenosine across the plasma membrane. 
In mice lacking ENT1 (ENT1
-/-
), we reported the development of ectopic mineralization 
of paraspinal tissues in the cervical-thoracic region at 2 months of age, which extended to 
the lumbar and caudal regions with advancing age. Histological examination revealed 
large, irregular accumulations of eosinophilic material in spinal fibrocartilaginous tissues 
including ligaments, entheses and intervertebral discs. Plasma adenosine levels were 
greater in ENT1
-/-
 mice than in wild-type controls and elevated plasma levels of inorganic 
pyrophosphate (PPi) in ENT1
-/- 
mice indicated generalized disruption of pyrophosphate 
homeostasis. This skeletal phenotype closely resembles a human disorder known as 
diffuse idiopathic skeletal hyperostosis (DISH). DISH is a relatively common non-
inflammatory spondyloarthropathy, characterized by ectopic calcification of spinal 
tissues. Its etiology is unknown and there are no specific treatments. The objectives of the 
present study were i) to characterize expression of adenosine transporters and receptors in 
spinal tissues; and ii) to investigate whether loss of ENT1 alters the expression of genes 
that regulate biomineralization, and/or genes involved in adenosine metabolism and 
signaling. Using quantitative RT-PCR, we compared gene expression in intervertebral 
disc tissues obtained from 6-month-old male ENT1
-/-
 and wild-type mice. No differences 
were observed in genes encoding nucleoside transporters, adenosine receptors or 
enzymes involved in adenosine metabolism. In contrast, intervertebral discs from ENT1
-/-
 
mice exhibited reduced expression of genes involved in suppressing biomineralization, 
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including: matrix gla protein (Mgp – an inhibitor of soft tissue mineralization); 
ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1 – responsible for the 
production of PPi, which inhibits mineralization); progressive ankylosis protein (Ank – a 
putative PPi transporter); and osteopontin (Spp1 – an inhibitor of mineralization). 
Unexpectedly, expression of alkaline phosphatase (Alpl – responsible for the hydrolysis 
of PPi to Pi) was also reduced in ENT1
-/-
 discs. Of note, no differences were observed in 
the expression of these genes in tissues, including knee and liver, which do not exhibit 
ectopic mineralization in ENT1
-/-
 mice. These findings suggest that alterations in 
regulatory proteins that normally prevent soft tissue mineralization contribute to the 
ectopic calcification of spinal tissues in ENT1
-/-
 mice. ENT1
-/-
 mice may be a useful 
model to investigate the etiology of and therapies for DISH and related disorders of 
mineralization in humans.  
 
3.2 Introduction  
Aberrant calcification of soft connective tissues has been associated with a 
number of skeletal disorders, such as diffuse idiopathic skeletal hyperostosis (DISH) (1). 
DISH is a common non-inflammatory condition of the spine (2). It involves the 
pathological calcification of the anterolateral spinal ligaments, entheses, and 
fibrocartilaginous tissues present in the intervertebral discs (1,3,4). DISH often presents 
as back pain and stiffness and is associated with increased vertebral fractures in the 
elderly (5) and in severe cases, dysphagia (6) and compression of the spinal cord and 
nerve roots (6-8). DISH is typically diagnosed by radiographic examination (9), and is 
associated with the detection of distinct calcified outgrowths along the vertebrae of the 
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thoracic spine or chest (2). The specific radiographic diagnostic criteria for DISH are 1) 
flowing calcifications along anterolateral aspect of at least four continuous vertebral 
bodies; 2) preservation of disc height in involved areas; and 3) absence of bony ankylosis 
of facet joints and absence of sacroiliac erosion, sclerosis or fusion (10). There have been 
no reported single gene defects associated with DISH, although single nucleotide 
polymorphisms in the COL6A1 and FGF2 genes have been shown to confer genetic 
susceptibility to DISH (11,12). Furthermore, several metabolic disorders are associated 
with DISH including obesity, hypertension, diabetes mellitus, dyslipidemia, and 
hyperuricemia (13-15).  
Recent studies have begun to investigate the role of purinergic signaling, 
specifically that of adenosine, in the physiology and pathophysiology of mineralized 
tissues (16). Through characterization of mice lacking ecto-5’-nucleotidase (Nt5e), 
Takedachi and colleagues demonstrated that adenosine promotes osteoblast 
differentiation via A2b adenosine receptor signaling (17). The Nt5e gene encodes the 
CD73 cell-surface enzyme, which converts adenosine monophosphate (AMP) to 
adenosine.  It was found that CD73
-/-
 mice had significantly lower bone mineral content 
than wild-type controls; these mice also showed a significant decrease in serum levels of  
osteocalcin, a metabolic marker of in vivo bone formation (17). Furthermore, real-time 
PCR demonstrated a decreased expression of osteoblast markers in CD73
-/-
 mice (17). 
Building on these studies, St. Hilarie et al. demonstrated that mutations in NT5E resulting 
in a non-functional CD73 enzyme show genetic associations with symptomatic arterial 
and joint calcifications in humans (18). In addition, cultured fibroblasts from affected 
individuals showed reduced expression of NT5E mRNA and the CD73 protein, increased 
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tissue-nonspecific alkaline phosphatase (ALPL) enzyme activity, and the accumulation of 
calcium phosphate crystals (18).  ALPL is an enzyme responsible for hydrolyzing 
inorganic pyrophosphate (PPi – an inhibitor of mineralization) to phosphate (Pi – which 
promotes calcification). These studies suggest a possible link between adenosine 
metabolism and ectopic mineralization. 
Recently, in mice lacking ENT1 (ENT1
-/-
 mice), we reported the development of 
ectopic mineralization in paraspinal tissues that resemble DISH (19). These mineralized 
lesions originate at the cervical-thoracic region as early as 2 months of age, and extend to 
the lumbar and caudal regions with advancing age (19). Histological examination 
revealed large, irregular accumulations of eosinophilic material in spinal 
fibrocartilaginous tissues including ligaments, entheses and intervertebral discs. 
Interestingly, plasma adenosine levels were found to be significantly greater in ENT1
-/-
 
mice than in wild-type controls (19).  
ENT1 (equilibrative nucleoside transporter 1 or solute carrier family 29 member 
1, encoded by the Slc29a1 locus) is a membrane protein involved in the bi-directional 
transport of nucleosides across the plasma membrane (20). The ENT1
-/-
 mouse was 
originally created by Dr. Choi and colleagues to study the role of adenosine transport in 
central nervous system pathways regulating alcohol consumption (21). Initial studies 
demonstrated that at 3 months of age, ENT1
-/- 
mice had <10% lower body weight, but 
showed no differences in open-field locomotor activity, and had no evidence of gross 
anatomical abnormalities in the brain compared to their wild-type littermate controls (21). 
Studies have reported that the ENT1
-/-
 mice consumed twice as much alcohol and 
demonstrated a decreased ataxic effect of ethanol (21). These mice were  also shown to 
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exhibit reduced anxiety-like behaviors (22). Microvascular endothelial cells isolated from 
ENT1
-/-
 mice have enhanced expression of the A2A adenosine receptor and adenosine 
deaminase (23). Cardiomyocytes from ENT1
-/- 
mice appear to be protected from ischemic 
insult and ENT1
-/-
 mice show decreased myocardial infarction in response to ischemia 
and hypoxia (24). 
The present study was conducted to understand the molecular framework 
underlying the development of ectopic mineralization in spinal tissues of the ENT1
-/-
 
mouse. We specifically interrogated gene expression differences in affected tissues 
isolated from ENT1
-/-
 mice compared to their age- and gender-matched littermate wild-
type controls to delineate the pathways through which disruption of adenosine signaling 
contribute to the development of soft connective tissue mineralization.  
 
3.3 Materials and Methods 
3.3.1 Animals 
 ENT1
-/-
 mice were generated through targeted deletion of exons 2 to 4 of the gene 
encoding ENT1 by a cre-loxP targeting strategy (21). ENT1
-/-
 mice were backcrossed 
with C57BL/6 mice. The mouse colony was maintained through the breeding of 
heterozygous animals (ENT1
+/-
) to obtain wild-type (ENT1
+/+
) and knockout (ENT1
-/-
) 
littermates. Mice were housed in standard cages and maintained on a 12-hour light/dark 
cycle, with rodent chow and water available ad libitum. Genotyping was performed as 
described (23). Given the increased reported prevalence of DISH in males (25% of men 
versus 15% of women over 50 years of age) (25), male mice were used for all 
experiments. Mice were euthanized at 6 months (26-30 weeks). All aspects of this study 
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were conducted in accordance with the policies and guidelines set forth by the Canadian 
Council on Animal Care and were approved by the Animal Use Subcommittee of the 
University of Western Ontario, London, ON.  
 
3.3.2 Isolation of Intervertebral Discs and RNA Extraction 
At 6 months of age, littermate-paired wild-type and ENT1
-/-
 mice (n=8 for each 
genotype) were dissected to isolate intact intervertebral discs (IVDs) inclusive of annulus 
fibrosus, nucleus pulposus and cartilage endplates. IVDs from each animal were 
separated according to anatomical location as cervical-thoracic, lumbar, or tail. Non-
affected tissues (including knee, heart, kidney, skeletal muscle, brain and liver) were also 
harvested from wild-type animals (n=3).  Tissues were placed directly in 1 mL of TRIzol 
Reagent (Life Technologies, Wilmington, DE) and homogenized using a PRO250 
Polytron benchtop homogenizer (PRO Scientific, Oxford, CT). Total RNA was extracted 
according to the manufacturer’s protocol and quantified using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Mississauga, ON). For each sample, 1 µg RNA 
was reverse transcribed into cDNA using Superscript II Reverse Transcriptase (Life 
Technologies).  
 
3.3.3 Primer Design and Optimization 
 For SYBR-based RT-PCR, primers were designed using PrimerBank and 
Integrated DNA Technologies with sequences specific to the gene of interest, to produce 
an amplicon between 75 to 175 bp in length. Whenever possible, primers were designed 
to flank an intron/exon boundary in order to detect gDNA contamination of RNA 
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samples. For primer optimization, the primers were assessed using serial dilutions (5-
fold) of cDNA synthesized from a mix of wild-type heart, brain, kidney, muscle, 
intervertebral disc, and calvarial RNA at a range of temperatures between 56-62
o
C to 
optimize annealing/elongation temperatures. Standard curves were generated to control 
for primer efficiency (70-120%) and specificity of primers were determined by melt 
curve analysis (0.5C/5 s).  
 
3.3.4 Quantitative real-time RT-PCR 
Gene expression patterns were determined by real-time PCR using the Bio-Rad 
CFX384 system. PCR reactions were run in triplicate, using 25 µM forward and reverse 
primers (primer sequences provided in Table 3.1) with 2X SsoFast EvaGreen Supermix 
(Bio-Rad, Mississauga, ON). The PCR program consisted of the following: initial 3 min 
at 95
o
C for denaturing; 95
o
C for 10 s denaturing; 30 s annealing/elongation (temperatures 
provided in Table 3.1), for a total of 40 cycles. Gene transcript levels were determined 
relative to a six-point calibration curve made from cDNA generated from heart, brain, 
kidney, muscle, intervertebral disc, and calvarial RNA (isolated from wild-type mice). 
The starting concentration of the cDNA standard (83 – 136 ng/µl) was inputted into the 
Bio-Rad CFX Manager 2.0 software to generate the standard curve (1/5 serial dilution). 
Values for gene transcript levels are expressed relative to the calibration curve in ng/µl.  
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Table 3.1: Real-time PCR Primer Sequences 
Gene 
Name 
Primer Sequence (5’ to 3’) 
  
Annealing/Elongation 
Temperature (
o
C) 
Ada Fwd – ACAATCAGAAGACCGTGGTGGCTA 
Rev – TCTTTACTGCGCCCTCATAGGCTT 
60 
Adk Fwd – CTCAGTGGTTGATTCAGGAGC 
Rev – CAGCCTTACGCTTCAGGATCT 
60 
Adora1 Fwd – ATCCCTCTCCGGTACAAGACAGT 
Rev – ACTCAGGTTGTTCCAGCCAAAC 
56 
Adora2a Fwd – CCGAATTCCACTCCGGTACA 
Rev – CAGTTGTTCCAGCCCAGCAT 
56 
Adora2b Fwd – ATGCAGCTAGAGACGCAAGAC 
Rev – GGGATACCAGAAAGTAGTTGGTG 
60 
Adora3 Fwd – ACTTCTATGCCTGCCTTTTCATGT 
Rev – AACCGTTCTATATCTGACTGTCAGCTT 
56 
Ank Fwd – CCCTGATAGCCTACAGTGACTTAGG 
Rev – GAAGGCAGCGAGATACAGGAA 
56 
Alpl Fwd – CCAACTCTTTTGTGCCAGAGAA 
Rev – GGCTACATTGGTGTTGAGCTTTT 
60 
Bglap Fwd – CTGACCTCACAGATCCCAAGC 
Rev – TGGTCTGATAGCTCGTCACAAG 
60 
Col10a1 Fwd – GGGACCCCAAGGACCTAAAG 
Rev – GCCCAACTAGACCTATCTCACCT 
60 
Enpp1 Fwd – CAAAACCCACAATGACTGTTGC 
Rev – CTGGACACTCCGGGGTATCG 
56 
ENT1 Fwd – CAAGTATTTCACAAACCGCCTGGAC 
Rev – GAAACGAGTTGAGGCAGGTGAAGAC 
56 
ENT2 Fwd – TCATTACCGCCATCCCGTACT 
Rev – CCCAGTTGTTGAAGTTGAAAGTG 
56 
ENT3 Fwd – AGCCTCACTCTTTCCAGCTGACAT 
Rev – ACTTGGTGTCTGTGTCGTTCCTGT 
60 
ENT4 Fwd – TGCTGTCCATTGCGGTAACCTACT 
Rev – TTGCCCACAAAGTCTGACAGGTTG 
56 
Gdf10 Fwd – GAAGTACAACCGAAGAGGTGC 
Rev – AGGCTTTTGGTCGATCATTTCC 
60 
Ibsp Fwd – ACGGCGATAGTTCCGAAGAG 
Rev – CTAGCTGTTACACCCGAGAGT 
60 
Mgp Fwd – GGCAACCCTGTGCTACGAAT 
Rev – CCTGGACTCTCTTTTGGGCTTTA 
56 
Nt5e Fwd - GGAGCTCACGATCCTGCACACAAA 
Rev – TCCCAGTGCCATAGCATCGTAGCC 
56 
Pnp Fwd - GCCGACTGGTGTTTGGATTGCTG 
Rev – TCGTTGCTCCCCCATTTGTTTCC 
56 
Runx2 Fwd - ATGGCTTGGGTTTCAGGTTAGGGA 
Rev – TGGAGTGAAGGATGAGGGCAAACT 
60 
Spp1 Fwd - AAGCAAGAAACTCTTCCAAGCAA 
Rev – GTGAGATTCGTCAGATTCATCCG 
56 
Xdh Fwd – ATGACCGCCTTCAGAACAAGA 
Rev – TGTCACAGCAACATGATGCAA 
60 
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3.3.5 Statistical Analyses 
Differences in gene expression levels between IVD tissues from distinct 
anatomical spine regions (cervical-thoracic, lumbar, and tail) and non-affected tissues 
(knee, heart, kidney, muscle, brain, and liver) within wild-type animals were compared 
using a one-way ANOVA with Bonferroni’s post-hoc test in GraphPad Prism 5 
(GraphPad Software, Inc., La Jolla, CA). For comparison of gene expression levels 
between wild-type and ENT1
-/-
 animals in IVD tissues isolated from specific anatomical 
regions, Student’s t-test analysis was conducted using GraphPad Prism 5. For all analysis, 
significance was indicated as p < 0.05. 
 
3.4 Results 
Our previous studies established that hypermineralization of the ENT1
-/-
 mouse 
was restricted to paraspinal fibrocartilaginous tissues and sternocostal articulations. In 
contrast, examination of appendicular joints revealed no aberrant morphology or 
evidence of ectopic mineralization, establishing that lesions are specifically associated 
with the axial skeleton. Furthermore, within the spine, there was a reproducible pattern of 
mineralization that progressed from cervical to caudal with age (19). We wanted to 
interrogate whether the temporal and spatial pattern of these hypermineralized lesions 
was due to differences in the levels of endogenous equilibrative nucleoside transporter 
and adenosine receptor expressions. 
Quantitative real-time PCR was performed to characterize the endogenous gene 
expression of equilibrative nucleoside transporters and adenosine receptors in distinct 
tissues of wild-type mice. The gene expression levels in IVDs from distinct anatomical 
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regions (cervical-thoracic, lumbar and tail) were compared to tissues not affected by 
hypermineralization in the ENT1
-/-
 mouse, which include the knee, heart, kidney, muscle, 
brain and liver. The knee sample included the entire joint, which encompassed 
fibrocartilaginous tissues of the meniscus and tendons, as well as articular cartilage and 
subchondral bone. The gene expression levels of ENT1 were found to be comparable 
between IVD tissues and other tissues examined (Fig 3.1A). In contrast, the expression of 
related transporters ENT2, ENT3, and ENT4 was significantly lower in the IVD and knee 
tissues compared to tissues of the heart, kidney and brain in which previous studies have 
reported robust ENT expression (26,27) (Fig. 3.1B-D). Plasma adenosine levels were 
found to be significantly greater in ENT1
-/-
 mice than in wild-type controls, and therefore 
it was logical to investigate whether the expression of adenosine receptors was altered in 
response to elevated adenosine levels. The gene expression levels of Adora1, Adora2b, 
and Adora3 in IVD tissues was significantly lower compared to tissues of the heart, 
kidney, and brain (Fig 3.2 A, C-D). However, the gene expression level of Adora2a in 
IVD tissues was significantly lower only when compared to tissues of the brain (Fig. 3.2 
B).   
Having established the endogenous distribution of adenosine transporters and 
receptors in IVD tissues in comparison to other tissue types, real-time PCR was then used 
to investigate whether loss of ENT1 alters the expression of genes associated with 
adenosine metabolism and signaling, or extracellular matrix mineralization in 
intervertebral disc tissues. For this analysis, IVD tissues were isolated from male ENT1
-/-
 
and wild-type littermate control mice at 6 months of age based on anatomical location. 
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Figure 3.1: Gene expression analysis of equilibrative nucleoside transporters in 
tissues isolated from 6-month-old wild-type mice.  
Real-time PCR analysis shows the gene expression of (A) ENT1, (B) ENT2, (C) ENT3, and 
(D) ENT4 in wild-type animals in intervertebral discs (IVD) isolated from the cervical-
thoracic (CT), lumbar or tail regions, knee, heart, kidney, muscle, brain and liver. Data are 
presented as the mean ± SEM, n = 8 animals for IVD, and n = 3 animals for other tissues. 
Values for gene transcript levels are expressed relative to a calibration curve in ng/µl as 
described in the materials and methods. Bars labeled with the same letter are not significantly 
different, based on one-way ANOVA with Bonferroni’s post-hoc test. 
A 
D 
C 
B 
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Figure 3.2: Gene expression analysis of adenosine receptors in tissues isolated from 
6-month-old wild-type mice.  
Real-time PCR analysis shows the gene expression of (A) Adora1, (B) Adora2a, (C) 
Adora2b, and (D) Adora3 for wild-type animals in intervertebral discs (IVD) isolated 
from the cervical-thoracic (CT), lumbar or tail regions, knee, heart, kidney, muscle, brain 
and liver. Data are presented as the mean ± SEM, n = 8 animals for IVD, n = 3 animals 
for other tissues. Bars labeled with the same lower case letter are not significantly 
different, based on one-way ANOVA with Bonferroni’s post-hoc test 
 
A 
C 
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D 
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Gene expression values for each transcript in heart tissue (isolated from wild-type mice) 
are presented as a positive control to compare relative abundance. We first interrogated 
the expression of genes encoding the ENT transporters to determine if there was a 
compensatory effect due to the loss of ENT1.  No significant differences were observed 
in the expression of ENT2, ENT3, or ENT4 between ENT1
-/-
 and wild-type mice within 
each anatomical region (Fig. 3.3). Similarly, there were no differences observed in the 
expression of adenosine receptors in ENT1
-/-
 mice compared to wild-type mice within 
each anatomical region (Fig. 3.4). 
Since ENT1 is the predominant nucleoside transporter expressed in mammalian 
cells, and plasma adenosine levels were found to be higher in ENT1
-/-
 mice than wild-type 
(19), we next investigated whether the expression of genes associated with the adenosine 
metabolism pathway were altered in the knockout mice. Adenosine kinase (Adk) is an 
enzyme that catalyzes the transfer of a phosphate from ATP to adenosine to form AMP; 
adenosine deaminase (Ada) metabolizes adenosine to inosine (another nucleoside); purine 
nucleoside phosphorylase (Pnp) is involved in the conversion of a nucleoside to a 
nucleobase, such as inosine to hypoxanthine; xanthine dehydrogenase (Xdh) catalyzes 
hypoxanthine to xanthine, and eventually to uric acid; and ecto-5'-nucleotidase (Nt5e) 
generates adenosine from the breakdown of AMP. No significant differences were 
observed in the expression of these adenosine metabolism enzymes in IVD tissues of 
ENT1
-/-
 mice compared to wild-type mice within each anatomical region (Fig. 3.5). 
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Figure 3.3: Gene expression analysis of equilibrative nucleoside transporters in 
intervertebral discs isolated from 6-month-old wild-type mice and ENT1
-/-
 mice. 
Real-time PCR analysis revealed no significant differences in the expression of (A) 
ENT2, (B) ENT3 or (C) ENT4 between wild-type and ENT1
-/-
 mice in specific spinal 
regions. Gene expression values for heart tissue isolated from wild-type mice only are 
presented as a positive control to compare relative abundance. Data are presented as the 
mean ± SEM, n = 8 animals. Black bar = WT and white bar = ENT1
-/-
 mice.   
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Figure 3.4: Gene expression analysis of adenosine receptors in intervertebral discs 
isolated from 6-month-old wild-type mice and ENT1
-/-
 mice.  
Real-time PCR analysis revealed no significant differences in the gene expression of (A) 
Adora1, (B) Adora2a, (C) Adora2b or (D) Adora3 between wild-type and ENT1
-/-
 mice in 
specific spinal regions. Gene expression values for heart tissue isolated from wild-type 
mice only are presented as a positive control to compare relative abundance. Data are 
presented as the mean ± SEM, n = 8 animals. Black bar = WT and white bar = ENT1
-/-
 
mice.  
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Figure 3.5: Gene expression analysis of adenosine metabolism genes in 
intervertebral discs isolated from 6-month-old wild-type mice and ENT1
-/-
 mice. 
Real-time PCR analysis revealed no significant differences in the expression of (A) Adk, 
(B) Ada, (C) Pnp, (D) Xdh or (E) Nt5e between wild-type and ENT1
-/-
 mice in specific 
spinal regions. Data are presented as the mean ± SEM, n = 8 animals. Black bar = WT 
and white bar = ENT1
-/-
 mice. α = significantly different between wild-type (p < 0.05, 
one-way ANOVA with Bonferroni’s post-hoc test).  
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Given that ENT1
-/-
 mice demonstrate progressive mineralization of paraspinal 
fibrocartilaginous tissues (19), we interrogated the expression of genes associated with 
extracellular matrix mineralization in IVD tissues. Compared to wild-type mice, we 
observed reduced expression of genes involved in suppressing biomineralization in 
ENT1
-/-
 mice, including matrix gla protein (Mgp – an inhibitor of soft tissue 
mineralization, Fig. 3.6A); ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1 – 
responsible for the production of pyrophosphate, PPi, which inhibits mineralization, Fig. 
3.6B); progressive ankylosis protein (Ank – a putative PPi transporter, Fig. 3.6C); and 
osteopontin (Spp1 – another inhibitor of mineralization, Fig. 3.6D). All four genes 
showed significantly reduced expression in ENT1
-/-
 mice compared to wild-type in IVDs 
isolated from the cervical-thoracic region, the anatomical region most severely affected 
by ectopic mineralization at the 6 month time point; Enpp1 also showed reduced 
expression in IVDs of the lumbar region of ENT1
-/-
 mice compared to wild-type gene 
expression levels (Fig. 3.6B). Importantly, no differences were observed in the expression 
of these genes between wild-type and ENT1
-/-
 mice in tissues of the knee or liver, which 
do not exhibit ectopic mineralization (Fig. 3.6). 
Unexpectedly, expression of tissue nonspecific alkaline phosphatase (Alpl) was 
found to be significantly decreased in IVDs of the cervical-thoracic and lumbar regions 
of ENT1
-/- 
mice compared to wild-type (Fig. 3.7). Tissue-nonspecific alkaline 
phosphatase is responsible for the hydrolysis PPi to Pi, which promotes mineralization 
(28). No differences were observed in the expression of Alpl between wild-type and 
ENT1
-/- 
mice in tissues of the knee or liver (Fig. 3.7).  
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Figure 3.6: Gene expression analysis of mineralization associated genes in 
intervertebral discs (IVD), knee, and liver isolated from 6-month-old wild-type mice 
and ENT1
-/-
 mice. 
Real-time PCR analysis of genes associated with tissue mineralization revealed 
significant reductions in the expression of (A) Mgp in the cervical-thoracic region, (B) 
Enpp1 in the cervical-thoracic and lumbar regions, (C) Ank in the cervical-thoracic 
region, and (D) Spp1 in the cervical thoracic region in ENT1
-/-
 mice compared to wild-
type controls. There were no significant differences in gene expression in the knee or 
liver of the ENT1
-/-
 mice compared to wild-type controls. Data are presented as the mean 
± SEM, n = 8 animals. Black bar = WT and white bar = ENT1
-/-
 mice. * Significantly 
different from same tissue isolated from wild-type (p < 0.05, Student’s t-test). 
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Figure 3.7: Gene expression analysis of alkaline phosphatase in intervertebral discs 
(IVD) isolated from 6-month-old wild-type mice and ENT1
-/-
 mice. 
Real-time PCR analysis revealed a significant reduction in the expression of Alpl for 
cervical-thoracic and lumbar regions in ENT1
-/-
 mice compared to wild-type controls. 
There were no significant differences in gene expression in the knee or liver in ENT1
-/-
 
mice compared to wild-type controls. Data are presented as the mean ± SEM, n = 8 
animals. Black bar = WT and white bar = ENT1
-/-
 mice. * Significantly different from 
same tissue isolated from wild-type (p < 0.05, Student’s t-test). 
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Our previous studies demonstrated that within fibrocartilaginous tissues, areas of 
ectopic calcification were surrounded by a clearly defined transition zone (19). Adjacent 
to fibrocartilaginous tissue with a typical histological appearance, this transition zone was 
characterized by metaplasia, with cells displaying eosinophilic nuclei that stained 
positively with DAPI, revealing an intact nuclear structure. To determine if cells within 
this tissue were undergoing a change in cell phenotype, we assessed the expression of 
markers associated with annulus fibrosus cells of the IVD (integrin binding sialoprotein, 
Ibsp, and growth differentiation factor 10, Gdf10), hypertrophic chondrocytes (runt 
related transcription factor 2, Runx2, and collagen, type X, alpha 1, Col10a1) and bone 
(Runx2 and osteocalcin, Bglap) lineage. Real-time PCR analysis revealed no differences 
in the expression of Ibsp (Fig 3.8A) but a significant reduction in the expression of Gdf10 
(Fig. 3.8B) in IVDs from the cervical-thoracic of ENT1
-/-
 mice compared to wild-type. No 
significant differences were detected in the expression of Runx2 or Col10a1 between 
wild-type and ENT1
-/-
 mice (Fig. 3.8C,D). In contrast, expression of Bglap was 
significantly reduced in IVDs from the cervical-thoracic region of the ENT1
-/-
 mice 
compared to wild-type (Fig. 3.8E). 
 
3.5 Discussion 
The first report of a role for the nucleoside transporter ENT1 in regulating 
biomineralization was the recent description by our group of  ectopic mineralization in 
fibrous connective tissues of the spine and sternum of ENT1
-/- 
mice (19). In these studies, 
ENT1
-/- 
mice were characterized at various ages (from 1 to 17 months of age) using a 
combination of histology and µCT imaging. Aberrant mineralization was first detected  
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Figure 3.8: Gene expression analysis of markers associated with phenotypic 
transition in intervertebral discs isolated from 6-month-old wild-type mice and 
ENT1
-/-
 mice. 
Real-time PCR analysis examining the expression of markers associated with the annulus 
fibrosus (A, B), hypertrophic chondrocyte (C, D) and osteoblast (C, E) phenotype. 
Quantification revealed significant reductions in the expression of (B) Gdf10 and (E) 
Bglap in the cervical-thoracic region of ENT1
-/-
 mice compared to wild-type controls. 
There were no significant changes in the expression of (A) Ibsp, (C) Runx2, (D) or 
Col10a1 in ENT1
-/-
 mice compared to wild-type controls.  Data are presented as the mean 
± SEM, n = 8 animals. Black bar = WT and white bar = ENT1
-/-
 mice. * Significantly 
different from same tissue isolated from wild-type (p < 0.05, Student’s t-test). 
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between 6-8 weeks of age in the paraspinal connectives tissues of the cervical vertebrae; 
lesions were found to increase in severity and affected the thoracic, lumbar, caudal spine  
and sternocostal articulations with advancing age. Atypical mineralization was initially 
observed in paraspinal fibrocartilaginous tissues including paraspinal ligaments and 
entheses, and later detected in the annulus fibrosus of intervertebral discs and sternocostal 
articulations.  
Despite a systemic loss of ENT1 function, our previous studies establish that 
ectopic mineralization in ENT1
-/- 
mice is limited to fibrocartilaginous paraspinal tissues 
and sternocostal articulations. While previous studies have characterized the relative 
expression of murine ENT genes in various tissue types (26,27), musculoskeletal tissues 
including the IVD were not included in these analyses. The present study shows that in 
wild-type mice, ENT1 mRNA levels within the IVD are similar to levels expressed in 
other tissue types such as the heart, kidney, muscle, brain and liver, while the mRNA 
levels of ENT2, ENT3 and ENT4 levels within the IVD are lower than tissues of the heart, 
kidney, and brain. Interestingly, tissues of the knee which do not demonstrate aberrant 
mineralization in ENT1
-/- 
mice (19), appeared to have lower levels of ENT1 gene 
expression than levels expressed in IVD tissues. The tissue-specific expression pattern of 
mouse ENT1 reported in the current study is consistent with previous reports, where 
ENT1 mRNA in male mice was found to be higher in the liver and similar in the heart, 
kidney, muscle and brain (26). The tissue distribution of ENT2 and ENT3 levels is also 
similar to the previous study (26).  
We further established an absence of compensatory upregulation of ENT2, ENT3, 
or ENT4 gene expression in IVD tissues of the ENT1
-/-
 mice. This is consistent with 
112 
 
previous studies that demonstrated gene expression levels of ENT2, ENT3, and ENT4 
were similar in cardiomyocytes isolated from ENT1
-/-
 mice compared with those isolated 
from wild-type littermates (24). Although a small but significant increase was reported in 
ENT3 transcript levels in microvascular endothelial cells of  ENT1
-/-
 mice compared to 
wild-type cells, no increase in ENT3 protein levels was detected (23). Taken together, 
these findings suggest that in tissues from ENT1
-/-
 mice, there appears to be no 
compensation by ENT2, ENT3, or ENT4 gene expression, with the lack of ENT1. 
Compared to other tissues which demonstrate detectable expression of multiple ENTs, we 
have shown the relative abundance of equilibrative nucleoside transporter levels in the 
IVDs, which demonstrate that the IVDs rely predominantly on ENT1. ENT1 has been 
established as a predominant nucleoside transporter in mammalian cells and 
consequently, it is then possible that with the absence of ENT1, the knockout mice 
develop an aberrant mineralized skeletal phenotype.  
Our previous studies demonstrated that plasma adenosine levels were 
significantly elevated in ENT1
-/- 
mice. Given the potential impact of disrupted adenosine 
signaling, we first investigated the endogenous expression of adenosine receptor 
expression in IVD tissues. The gene expression levels of Adora1, Adora2b, and Adora3 
in IVD tissues was significantly lower compared to tissues such as the heart, kidney, and 
brain. However, the gene expression level of Adora2a in IVD tissues was significantly 
lower only when compared to tissues of the brain. Our findings are consistent with 
previous studies that reported expression of Adora1 throughout the central nervous 
system (CNS), heart, kidney and liver (29) and  Adora2a expression in the CNS (29) and 
heart (30). Previous studies suggest a more widespread expression of Adora2b; whereas 
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Adora3 expression has been reported to be enriched in brain tissues and liver,  detected in 
the heart and kidney, and not detected in skeletal muscle (29). Compared to tissues of the 
heart, kidney, and brain, we have observed low gene expressions of adenosine receptors 
in the IVDs, which suggests that the presence of adenosine receptors may not play a big 
role in the development of the skeletal phenotype observed in the ENT1
-/-
 mice.   
Although we have shown that there are elevated plasma adenosine levels in the 
ENT1
-/-
 mice, we have yet to investigate the levels of adenosine within the spinal tissue. 
Similar to our findings for ENT gene expression, no significant differences in the 
expression of adenosine receptors were detected in ENT1
-/-
 mice compared to wild-type 
mice. A lack of change in the mRNA levels of adenosine receptors suggests that protein 
levels of adenosine receptors may not change. However, it is likely that adenosine 
receptor signaling is different in ENT1
-/-
 mice because of differences in the extracellular 
concentration of adenosine, or changes in intracellular signal coupling. Previous reports 
suggest that changes in adenosine receptor expression in ENT1
-/-
 mice may be cell-type 
dependent. In cardiomyocytes isolated from ENT1
-/-
 mice, no significant differences were 
reported in the expression of adenosine receptor subtypes (24), whereas enhanced 
expression of Adora2a was reported in microvascular endothelial cells isolated from 
ENT1
-/-
 mice (23). Furthermore, suggesting that loss of ENT1 does not alter adenosine 
metabolism in IVD tissues, we demonstrate no significant differences in the expression of 
adenosine metabolism enzymes (Adk, Ada, Pnp, Xdh, Nt5e) in ENT1
-/-
 mice compared to 
wild-type control. Gene expression studies suggest that at 6 months of age, adenosine 
signaling and metabolism pathways do not appear to be altered in IVD tissues of ENT1
-/-
 
mice, but further studies are required to assess levels of adenosine within our tissue of 
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interest and measure active signaling.  
Previous studies have demonstrated that purine metabolism and signaling play a 
critical role in the regulation of biomineralization and diseases associated with aberrant 
mineralization (9,16,18,31-33). In the current study, we report a significant decrease in 
Mgp expression in IVD tissues of ENT1
-/-
 mice isolated from anatomical regions that 
demonstrate ectopic mineralization at 6 months. MGP is an extracellular matrix 
glycoprotein that contains γ-carboxyl groups, which allow it to chelate calcium and 
function as an inhibitor of tissue mineralization (34). MGP deficiency in mice results in 
premature calcification, aberrant mineralization of growth plate cartilage, leading to short 
stature, osteopenia and fractures, and severe arterial calcification leading to premature 
death (35). The corresponding human disorder is known as Keutal syndrome, 
characterized by abnormal cartilage calcification, peripheral pulmonary stenosis and 
midfacial hypoplasia (36). In addition, the tiptoe walking mouse (ttw, a spontaneous 
recessive mutant), shows disruption of the annulus fibrosus arrangement in IVDs and has 
been suggested to be associated with the abnormal expression of MGP (37). Interestingly, 
SPP1 is also a putative inhibitor of mineralization (38,39) and we demonstrate that its 
expression is downregulated in IVD tissues of ENT1
-/-
 mice in regions associated with 
ectopic mineralization at 6 months. Decreased expressions of these inhibitors of tissue 
mineralization contribute to the ectopic mineralization observed in the ENT1
-/-
 mice.     
When ATP is released by the cell, it is sequentially metabolized by cell-surface 
enzymes to produce adenosine. ENPP1 is responsible for the first step in this process and 
serves as a physiological regulator of calcification via the production of adenosine 
monophosphate (AMP) and inorganic pyrophosphate (PPi), the latter of which inhibits 
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ectopic calcification in soft tissues (40). Extracellular PPi is also regulated by ANK, a 
transmembrane protein postulated to transport PPi across the plasma membrane to the 
extracellular environment (41). We show a significant downregulation of Enpp1 and Ank 
expression in IVD tissues of ENT1
-/-
 mice in regions of associated ectopic mineralization 
at 6 months of age. Enpp1
-/-
 mice have been shown to exhibit soft tissue mineralization in 
paraspinal ligaments, intervertebral discs, Achilles tendon and calcification of articular 
cartilage, and peripheral joint hyperostosis (28). Mutations in Enpp1 have been also been 
linked to mineralization disorders such as ossification of the posterior longitudinal 
ligament (42) and generalized arterial calcification of infancy and hypophosphatemic 
rickets (43). In mice, mutations in Ank lead to mineral deposition in the articular cartilage 
and synovial fluid (41,44), and eventual generalized joint fusion (45,46). In humans, 
dominant ANK mutations are associated with craniometaphyseal dysplasia (47,48) and 
familial chondrocalcinosis (49,50). Therefore, we postulate that reduced expression of 
Enpp1and Ank would lead to reduced extracellular PPi levels, and thus increased tissue 
mineralization.  
Interestingly, the changes in gene expression associated with the regulation of 
mineralization were found to correlate with the temporal progression of mineralization 
reported in ENT1
-/-
 mice  (19). At the 6 month time point examined in these studies, 
mineralization was reported in >60% of the cervical and thoracic spine, 30% of the 
lumbar spine, and was not detected in the caudal spine. The fact that significant changes 
in Mgp, Enpp1, Ank, and Spp1 gene expression were restricted to IVDs of the cervical-
thoracic spine of ENT1
-/-
 mice suggests that observed changes are secondary to the 
initiation of mineralization. Furthermore, no significant differences were observed in the 
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expression of these genes in other tissues including the knee and liver, which do not 
exhibit ectopic mineralization in ENT1
-/-
 mice. We also observed that gene expression in 
caudal IVDs is different from the gene expression in cervical-thoracic and lumbar IVDs 
in wild-type mice. Real-time PCR analysis revealed a significantly higher expression of 
ENT4 and Adora3 in the tail IVDs compared to the lumbar IVDs; expression of Xdh was 
significantly lower in the tail IVDs compared to the cervical-thoracic IVDs; and Mgp 
expression was significantly higher in tail IVDs compared to cervical-thoracic IVDs. It is 
possible that these differences in gene expression contribute to the fact that the tail IVDs 
are the last to demonstrate ectopic mineralization in the spine. Further studies are 
required to explore the mechanism(s) underlying this phenomenon.  
Unexpectedly, expression of Alpl was significantly reduced in IVDs of the 
cervical-thoracic and lumbar spine of ENT1
-/-
 mice compared to control tissue. ALPL 
promotes mineralization by catalyzing the hydrolysis of PPi, thereby decreasing the local 
concentration of this calcification inhibitor, while increasing the levels of Pi (28). Alpl
-/-
 
mice mimic a severe form of hypophosphatasia, characterized by rickets, spontaneous 
bone fractures, osteomalacia, and elevated PPi levels, and die before weaning (51). In 
humans, disruption of ALPL causes hypophosphatasia, characterized by skeletal 
hypomineralization (52). It is possible that the reduction of Alpl in the spinal tissues of 
ENT1
-/- 
mice at 6 months of age (at which age lesions are present in the cervical, thoracic 
and lumbar regions) is a result of excessive mineral present in the extracellular matrix. As 
a consequence, lower levels of Alpl would attempt to decrease further mineralization. 
In our initial characterization of ENT1
-/-
 mice, we noted that early foci of 
mineralization in fibrocartilaginous structures were associated with a clearly defined 
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transition zone that contained cells with eosinophilic nuclei and a hypertrophic 
appearance (19). To begin to examine whether ectopic mineralization was associated with 
a phenotypic conversion of the associated fibrocartilaginous cell types, we examined the 
expression of cell-type specific markers. To investigate the disruption of the annulus 
fibrosus phenotype, we quantified the expression of Ibsp and Gdf10. While levels of Ibsp 
expression were unchanged, a significant reduction in the expression of Gdf10 was 
detected in IVDs from the cervical-thoracic region of ENT1
-/-
 mice compared to wild-
type tissues, which may suggest alterations in the annulus fibrosus phenotype. No 
differences were detected in the expression of either Runx2 or Col10a1 in IVD tissues 
from ENT1
-/-
 mice compared to wild-type, markers associated with the osteoblast (53) 
and hypertrophic chondrocyte lineages (54,55). In contrast, expression of osteocalcin 
(Bglap), an abundant non-collagenous bone matrix protein, which has been previously 
reported to be specific to osteoblasts (56,57), was significantly reduced in IVDs of the 
cervical-thoracic region of the ENT1
-/-
 mice compared to wild-type tissues. There have 
been contradictory results over the role of osteocalcin in bone mineralization. Ducy et al. 
showed that osteocalcin-deficient mice had increased bone density without a change in 
bone resorption or mineralization, suggesting that osteocalcin directly inhibits 
osteoblastic bone formation (58). However, some studies show a positive correlation 
between osteocalcin concentration and mineralization (59). Furthermore, the involvement 
of osteocalcin in bone resorption has also been demonstrated, principally in the regulation 
of osteoclast formation and activity (60,61). Despite controversial data, the dual role of 
osteocalcin in bone can be presumed: firstly, osteocalcin regulates bone remodeling by 
modulating osteoblasts and osteoclast activity, secondly, it acts as a regulator of bone 
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mineralization (62). Taken together, these results suggest that the development of ectopic 
lesions within the fibrocartilaginous tissue of the IVD in ENT1
-/-
 mice is not associated 
with the phenotypic conversion of annulus fibrosus cells to either a hypertrophic 
chondrocyte or osteoblastic lineage. Further studies are required to understand the 
specific cellular changes associated with the metaplasia and initiation of tissue 
mineralization in ENT1
-/-
 mice.  
In summary, the present study was conducted to begin to elucidate the molecular 
framework underlying the progressive mineralization of paraspinal tissues in the ENT1
-/-
 
mouse. The pattern of ectopic mineralization observed in ENT1
-/- 
mice is intriguing as 
pathological changes are restricted to the spine and sternocostal regions, despite being a 
whole-body knockout of ENT1 and demonstrates a reproducible temporal pattern of 
development (19,21). The current data suggests that spinal tissues may be affected by 
ectopic mineralization due to the endogenous expression of ENTs, which shows that 
ENT1 is the predominant nucleoside transporter in IVDs. Furthermore, as demonstrated 
by real-time PCR, there appears to be no compensation by related transporters for the loss 
of ENT1. The data also shows significant changes in the expression of genes involved in 
the suppression of biomineralization that may contribute to calcification. Since there is a 
downregulation of mineralization associated genes, pathogenesis also appears to be 
associated with changes in PPi homeostasis. In addition, although the annulus fibrosus is 
affected in the IVD with lesions, changes do not appear to be correlated with the 
phenotypic conversion of annulus fibrosus cells to either a hypertrophic chondrocyte or 
osteoblast lineage. A limitation of this study was the targeted candidate gene approach 
used to evaluate changes in gene expression; furthermore, these changes are yet to be 
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verified by protein data. In order to investigate changes associated with the early 
induction of tissue mineralization, we propose that identification of primary changes will 
require a more global approach to analysis, including microarray or proteomic 
quantification at an earlier time-point. Understanding the ENT1
-/- 
mouse may be 
advantageous for investigating the mechanisms of ectopic mineralization observed in 
DISH and associated mineralization disorders. 
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4.1 Summary and Conclusions 
The studies presented in this thesis were undertaken based on a preliminary 
observation that mice lacking the gene encoding ENT1 developed progressive ectopic 
mineralization of spinal tissues. We hypothesized that: loss of ENT1 leads to 
progressive accumulation of ectopic mineral in paraspinal tissues due to altered 
expression of genes that regulate biomineralization.  
We sought to explore this hypothesis with the following specific objectives: 
1) Characterize pathological changes in paraspinal tissues in ENT1-/- mice over time 
pertaining specifically to hypermineralization. 
2) Determine changes in the expression of genes associated with adenosine transport 
and metabolism, as well as, extracellular matrix mineralization in the ENT1
-/-
 
mice compared to wild-type controls. 
 
In chapter two, we characterized the temporal and spatial pattern of the 
mineralized lesions present in the ENT1
-/-
 mice.  
Conclusion 2.1: Mice lacking functional ENT1 demonstrate ectopic mineralization 
restricted to paraspinal, intervertebral and sternocostal fibrocartilaginous tissues. There 
was no evidence of mineralization in appendicular joints or blood vessels, indicating 
specificity of the axial skeleton.  
Conclusion 2.2: ENT1
-/-
 mice demonstrate a reproducible temporal pattern of 
mineralization which originates in the cervical paraspinal ligaments at 2 months of age, 
and extends towards the thoracic, lumbar, and caudal region with age involving 
intervertebral disc (IVD) tissues and sternocostal joints.   
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Conclusion 2.3: Micro-computed tomography (µCT) imaging of radio-opaque 
mineralized lesions in the spinal tissues of ENT1
-/-
 mice bear striking resemblance to the 
radiographic appearance of spinal lesions characteristic of diffuse idiopathic skeletal 
hyperostosis (DISH) in humans. 
 
In chapter three, we investigated the molecular framework underlying the 
development of ectopic mineralization of spinal tissues in the ENT1
-/-
 mouse. We first 
characterized the endogenous expression of nucleoside transporters and adenosine 
receptors in spinal tissues, and then interrogated gene expression differences in affected 
tissues isolated from ENT1
-/-
 mice compared to their age- and gender-matched littermate 
wild-type controls. Using a targeted candidate gene approach, these studies sought to 
delineate the pathways through which disruption of adenosine signaling contribute to the 
development of soft connective tissue mineralization.  
Conclusion 3.1:  In wild-type mice, the gene expression levels of ENT1 within the IVDs 
are similar to levels expressed in other tissue types such as the heart, kidney, muscle, 
brain and liver. In contrast, the gene expression levels of related transporters, ENT2, 
ENT3, and ENT4 were significantly lower in the IVD and knee tissues compared to 
tissues of the heart, kidney and brain.  
Conclusion 3.2: Compared to wild-type, expression of genes encoding nucleoside 
transporters, adenosine receptors, or enzymes involved in adenosine metabolism were not 
altered in IVDs isolated from ENT1
-/-
 mice.  
Conclusion 3.3: Gene expression findings suggest that decreased gene expression of 
regulatory proteins that normally prevent soft tissue mineralization (Mgp, Enpp1, Ank, 
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Spp1) may contribute to the ectopic calcification of spinal tissues in ENT1
-/-
 mice. 
Furthermore, elevated plasma levels of inorganic PPi in ENT1
-/- 
mice indicate generalized 
disruption of pyrophosphate homeostasis. 
 
4.2 Significance of Research 
Is the ENT1
-/- 
mouse a model for diffuse idiopathic skeletal hyperostosis (DISH)? 
DISH is a common human disorder which involves the calcification of the 
anterior longitudinal ligament, paraspinal connective tissues and annulus fibrosus (1,2). 
DISH is often underdiagnosed and widely misdiagnosed (3); this is due to the fact that it 
is primarily diagnosed though radiographs of the thoracic spine or chest, which are 
usually taken due to another disease or injury (4). The etiology of DISH is unknown, and 
currently there are no specific treatments. It has been proposed that lesions originate in 
fibrous and fibrocartilaginous structures including entheses, however the underlying 
pathogenesis remains obscure since prior to our studies, no suitable animal model had 
been reported to pursue mechanistic studies.  
In this study, we observed that the lesions of ectopic mineralization present at the 
cervical and upper thoracic regions of ENT1
-/-
 mice resemble the radiographic appearance 
of lesions present in patients diagnosed with DISH. The ectopic calcification observed in 
the ENT1
-/- 
mice is restricted to paraspinal ligaments, entheses, intervertebral discs and 
sternocostal regions. However, it is important to note that although the thoracic spine is 
most commonly affected, appendicular joints such as metacarpophalangeal joints, 
elbows, and shoulders are also affected in DISH (5-9). Entheseal ossification of the heel, 
ribs, and pelvis are also common findings in DISH (5).  
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Equilibrative nucleoside transporters (ENTs) are sodium-independent, facilitative 
diffusion transporters which transport nucleosides bi-directionally down a concentration 
gradient. ENTs are found distributed among various cell types (10,11) and consist of four 
members (ENT1, ENT2, ENT3, ENT4) which share an ability to transport adenosine but 
differ in their abilities to transport other nucleosides and molecules (12). Recent advances 
point to a critical role for purine metabolism in the regulation of biomineralization in 
diseases associated with either insufficient or ectopic mineralization (13-18). Our studies 
(Chapter 2) are the first to report a role of the primary membrane transporter for 
adenosine – ENT1 – in regulating soft tissue calcification in mice.  
Loss of ENT1 activity would be expected to modify extracellular adenosine 
levels, thus altering overall purine metabolism and signaling through adenosine receptors. 
In the present study, we found that plasma adenosine concentrations are significantly 
elevated in the ENT1
-/- 
mice compared to wild-type littermates. The increased plasma 
concentration of adenosine in ENT1
-/- 
mice likely reflects extracellular accumulation of 
adenosine due to the lack of uptake by cells that normally express ENT1 – one of the 
primary uptake pathways for adenosine (12,19). The role of elevated extracellular 
adenosine in the formation of abnormal mineral deposits in fibrocartilaginous tissues 
remains to be explored, but may involve local changes in adenosine receptor signaling, 
which in turn alter the expression of genes important for the regulation of 
biomineralization. A recent study has linked ectopic arterial and joint calcifications with 
loss of ecto-5'-nucleotidase (NT5E) function leading to decreased levels of extracellular 
adenosine (15), and therefore implicates aberrant adenosine signaling in the pathogenesis 
of arterial calcification. 
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The gene expression data demonstrates reduced expression of genes involved in 
suppressing biomineralization, such as Mgp, Enpp1, Ank, and Spp1, which could explain 
the ectopic mineralization observed in the ENT1
-/- 
mice. It is also possible that the 
reduction of Alpl in the spinal tissues of ENT1
-/- 
mice is a result of excessive mineral 
present in the extracellular matrix. As a consequence, lower levels of Alpl would attempt 
to decrease further mineralization.This data suggests that altered adenosine levels lead to 
changes in pathways associated with mineralization signaling, specifically in the 
expression of enzymes regulating PPi and secreted proteins that regulate 
biomineralization (Fig. 4.1). 
In conclusion, the ENT1
-/- 
mouse may prove useful as a model for investigating 
the mechanisms underlying the onset and progression of ectopic mineralization 
associated with DISH and other mineralization disorders. This may lead to the 
identification of risk factors, and for the evaluation of therapies for the prevention and 
reversal of DISH and associated pathologies. The findings will represent a breakthrough 
in our understanding of this common but as yet under-recognized disease.  
 
4.3 Limitations of the Research and Suggestions for Future Studies 
The present study was the first to report the skeletal phenotype of the ENT1
-/- 
mouse. As such, there are many future studies that can be undertaken using this model. In 
Chapter 3, we performed gene expression experiments which demonstrated a down-
regulation of genes that regulate biomineralization (Mgp, Enpp1, Ank, Spp1, and Alpl) in 
ENT1
-/- 
mice. However, we are unable to make any conclusive statements about a  
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Figure 4.1: Proposed schematic of pathways regulating biomineralization in the 
ENT1
-/- 
mouse.  
In contrast to Figure 1.2, which demonstrates the pathway for physiological 
biomineralization, results from these studies demonstrate disruption of these pathways in 
the ENT1
-/- 
mice. The fibrocartilage cell appears to be the cell type affected in the ENT1
-/- 
mice. Plasma adenosine levels are significantly elevated in the ENT1
-/- 
mice compared to 
the wild-type due presumably to the loss of ENT1-mediated transport. Under normal 
conditions, ATP is released extracellularly and subsequently metabolized by cell-surface 
enzymes. Our studies demonstrate a significant decrease in the expression of 
ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1), an enzyme that 
metabolizes ATP and releases inorganic pyrophosphate (PPi, which inhibits 
mineralization). There is also a decrease in the expression of progressive ankylosis (Ank), 
a putative transporter that mediates PPi efflux. A decrease in ENPP1 and ANK levels 
would result in lower levels of the mineralization inhibitor PPi, thus allowing for 
mineralization to proceed. Our studies also show a decrease in the expression of 
mineralization inhibitors, matrix Gla protein (Mgp) and osteopontin (Spp1), which could 
explain the ectopic mineralization observed in the ENT1
-/- 
mice. PPi is metabolized by 
alkaline phosphatase (Alpl), which produces inorganic phosphate (Pi), promoting 
mineralization. Pi and Ca
2+
 accumulate in matrix vesicles or on extracellular matrix 
components resulting in the crystallization of calcium phosphate, leading to formation of 
hydroxyapatite and thus, matrix calcification. Pathogenesis appears to be associated with 
the dysregulation of biomineralization pathways, and may involve both local and 
systemic changes in PPi homeostasis, or PPi:Pi ratio. 
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mechanism for ectopic mineralization, without any protein data. Therefore, it is necessary 
to follow-up the differences we observed in gene expression with analysis of protein data 
or assays of enzymatic activity. Additionally, the global differences in protein levels 
between the ENT1
-/- 
mouse and age-and-gender matched wild-type controls could also be 
assessed using mass spectrometry-based proteomics. 
In our studies, characterization of gene expression was performed on 6-month old 
mice, at which age lesions were present in varying degrees in the spine; mineralization 
was reported in 60 to 90% of the cervical spine, 30 to 60% of the thoracic spine, 0 to 30% 
of the lumbar spine, and not detected in the caudal spine. Detected changes in gene 
expression were restricted to IVD tissues in the presence of mineralized lesions and 
therefore it is likely that the differences we observed are due to a secondary effect (the 
presence of ectopic mineralization). Therefore, in order to delineate the pathway(s) 
responsible for the development of hypermineralized lesions, gene expression studies 
should be carried out at a younger time-point, such as 1-2 month-old mice when lesions 
are first detectable by µCT. A non-biased global analysis for gene expression of ENT1
-/- 
mouse tissues (by microarray), may be necessary to identify causative factors for the 
observed ectopic mineralization. Furthermore, it should be noted that although lesions are 
encapsulated by the annulus fibrosus in the IVDs, gene expression studies were carried 
out on the entire IVDs, which included three different tissue types. Therefore, the existing 
research is technically limited as we were unable to micro-dissect the tissue of interest (in 
the lab, studies are currently undergoing in order to isolate cells of the annulus fibrosus).   
In addition to genetic approaches, it would be interesting to test whether long-
term administration of ENT1 blockers leads to the development of DISH in wild-type 
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mice. These in vivo pharmacological studies would help determine whether loss of ENT1 
activity leads directly to abnormal mineralization, or whether it acts indirectly through a 
developmental defect that in turn impacts biomineralization. Administration of 
nitrobenzylmercaptopurine riboside (NBMPR), which is a specific inhibitor of ENT1 
(20), to wild-type animals, would allow us to investigate whether animals develop 
mineralization of spinal tissues similar to the phenotype observed in ENT1
-/- 
mice.  
A critical issue arises from our findings to date: ENT1 function was compromised 
in all tissues and extracellular adenosine and PPi levels were systemically elevated, yet 
ectopic calcification was limited to paraspinal tissues. There was no calcification in blood 
vessels, cartilage and other soft connective tissue (including fibrocartilaginous structures 
of the appendicular skeleton). Gene expression data does not show compensation by 
other related transporters (ENT2, ENT3, and ENT4) for the loss of ENT1 in spinal tissues, 
however, it is possible that in non-spinal tissues, there is an upregulation of other 
transporters or the endogenous expression of related ENT transporters compensates for 
the loss of ENT1. Alternatively, changes in expression of Mgp, Enpp1, Ank, Spp1, and 
Alpl may not occur in non-spinal tissues, because of tissue-specific differences in 
signaling. Further studies are required to better understand the tissue specificity of the 
ENT1
-/-
 phenotype. 
Interestingly, the Boxer dog breed exhibits an unusually high incidence of DISH 
(41% prevalence) (21), and has a 7-amino-acid deletion in a critical region of ENT1 that 
may impact transport function (22). The high prevalence in a particular breed and the 
relative absence of the disease in other breeds is consistent with a genetic origin. 
Therefore, it is possible that ENT1 function is compromised in the Boxer dog. Tissue 
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samples from Boxer dogs, as well as from humans diagnosed with DISH, will provide 
information on whether there is a genetic association between mutations or single 
nucleotide polymorphisms in the ENT1 gene and DISH.  
Lastly, in vitro studies provide important insights into fundamental mechanisms 
of biological processes. Cell and tissue culture models allow for manipulation of the 
system, and could be used to investigate the mechanism that underly changes in gene 
expression and excessive mineralization. To mimic hypermineralization in wild-type 
cells, ENT blockers such as NBMPR, or elevated extracellular concentration of 
adenosine could be used. Furthermore, in vitro experiments to attempt to “rescue” 
hypermineralization in ENT1
-/-
 cells would be informative, and can be done by 
maintaining the concentration of extracellular adenosine at physiological levels, and/or 
through the use of selective adenosine receptor antagonists to block adenosine signaling 
via A1, A2a, A2b or A3 receptors.  
The experiments outlined above will provide insight into the mechanism 
underlying the development of ectopic mineralization in ENT1
-/-
 mice and hopefully 
provide a means to correlate this mechanism with biochemical and gene expression 
changes in human DISH patients to determine the mechanism in humans.  
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AUP Title: Purine and Pyrimidine Transport in the Cardiovasculature 
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The YEARLY RENEWAL to Animal Use Protocol (AUP) 2009-030 has been approved. 
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2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the 
ACVS office. 
Health certificates will be required. 
 
REQUIREMENTS/COMMENTS 
Please ensure that individual(s) performing procedures on live animals, as described 
in this protocol, are familiar with the contents of this document. 
The holder of this Animal Use Protocol is responsible to ensure that all associated 
safety components (biosafety, radiation safety, general laboratory safety) comply 
with institutional safety standards and have received all necessary approvals. Please 
consult directly with your institutional safety officers. 
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